Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Pearson, A. Proszek, P. Pascual, J. Fribbens, C. Shamsher, M.K. Kingston, B. O'Leary, B. Herrera-Abreu, M.T. Cutts, R.J. Garcia-Murillas, I. Bye, H. Walker, B.A. Gonzalez De Castro, D. Yuan, L. Jamal, S. Hubank, M. Lopez-Knowles, E. Schuster, E.F. Dowsett, M. Osin, P. Nerurkar, A. Parton, M. Okines, A.F. Johnston, S.R. Ring, A. Turner, N.C. (2020). Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance. Clinical cancer research, Vol.26 (3), pp. 608-622.

Buus, R. Sestak, I. Barron, S. Loughman, T. Fender, B. Ruiz, C.L. Dynoodt, P. Wang, C.-. O'Leary, D. Gallagher, W.M. Dowsett, M. Cuzick, J. (2020). Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study. Clinical cancer research, Vol.26 (3), pp. 623-631.

Cuzick, J. Sestak, I. Forbes, J.F. Dowsett, M. Cawthorn, S. Mansel, R.E. Loibl, S. Bonanni, B. Evans, D.G. Howell, A. (2020). Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. The lancet, Vol.395 (10218), pp. 117-122.

(2020). ‘Breast cancer biomarkers in clinical testing: analysis of a UK NEQAS ICC & ISH database containing results from 199 300 patients’. The journal of pathology: clinical research, Vol.6 (3), pp. 227-227.

Chopra, N. Tovey, H. Pearson, A. Cutts, R. Toms, C. Proszek, P. Hubank, M. Dowsett, M. Dodson, A. Daley, F. Kriplani, D. Gevensleben, H. Davies, H.R. Degasperi, A. Roylance, R. Chan, S. Tutt, A. Skene, A. Evans, A. Bliss, J.M. Nik-Zainal, S. Turner, N.C. (2020). Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nature communications, Vol.11 (1).

Dowsett, M. Ellis, M.J. Dixon, J.M. Gluz, O. Robertson, J. Kates, R. Suman, V.J. Turnbull, A.K. Nitz, U. Christgen, M. Kreipe, H. Kuemmel, S. Bliss, J.M. Barry, P. Johnston, S.R. Jacobs, S.A. Ma, C.X. Smith, I.E. Harbeck, N. (2020). Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic. Npj breast cancer, Vol.6 (1).

Woolf, D.K. Li, S.P. Detre, S. Liu, A. Gogbashian, A. Simcock, I.C. Stirling, J. Kosmin, M. Cook, G.J. Siddique, M. Dowsett, M. Makris, A. Goh, V. (2019). Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. Biomarkers in cancer, Vol.11, pp. 1179299X1985151-1179299X1985151.

Rimm, D.L. Leung, S.C. McShane, L.M. Bai, Y. Bane, A.L. Bartlett, J.M. Bayani, J. Chang, M.C. Dean, M. Denkert, C. Enwere, E.K. Galderisi, C. Gholap, A. Hugh, J.C. Jadhav, A. Kornaga, E.N. Laurinavicius, A. Levenson, R. Lima, J. Miller, K. Pantanowitz, L. Piper, T. Ruan, J. Srinivasan, M. Virk, S. Wu, Y. Yang, H. Hayes, D.F. Nielsen, T.O. Dowsett, M. (2019). An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Modern pathology, Vol.32 (1), pp. 59-69.

Willis, S. Polydoropoulou, V. Sun, Y. Young, B. Tsourti, Z. Karlis, D. Long, B. Lin, X. Theel, S. Carlson, J. Győrffy, B. Williams, C. Abramovitz, M. Dafni, U. Dowsett, M. Leyland-Jones, B. (2019). Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab. Jco precision oncology, (2), pp. 1-12.

SONNENBLICK, A. BAILEY, A. UZIELY, B. UNTCH, M. SMITH, I.A. GIANNI, L. BASELGA, J. JACKISCH, C. CAMERON, D. BELL, R. ZARDAVAS, D. AL-SAKAFF, N. GELBER, R.D. DOWSETT, M. LEYLAND-JONES, B. PICCART-GEBHART, M.J. DE AZAMBUJA, E. (2019). Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer research, Vol.39 (2), pp. 797-802.

Dowsett, M. (2019). Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. Jnci cancer spectrum, .

Richman, J. Dowsett, M. (2019). Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nat rev clin oncol, Vol.16 (5), pp. 296-311.  show abstract

Leal, M.F. Haynes, B.P. MacNeill, F.A. Dodson, A. Dowsett, M. (2019). Comparison of protein expression between formalin-fixed core-cut biopsies and surgical excision specimens using a novel multiplex approach. Breast cancer research and treatment, Vol.175 (2), pp. 317-326.

Boddington, C. Bradley, R. Braybrooke, J. Burrett, J. Clarke, M. Davies, C. Davies, L. Dodwell, D. Duane, F. Evans, V. Gettins, L. Godwin, J. Gray, R. Hills, R. James, S. Liu, H. Liu, Z. MacKinnon, E. Mannu, G. McGale, P. McHugh, T. Morris, P. Pan, H. Peto, R. Read, S. Taylor, C. Wang, Y. Wang, Z. Bradley, R. Braybrooke, J. Gray, R. Bergh, J. Peto, R. Gray, R. Bradley, R. Braybrooke, J. Liu, Z. Peto, R. Davies, L. Dodwell, D. McGale, P. Pan, H. Taylor, C. Barlow, W. Bliss, J. Bruzzi, P. Cameron, D. Fountzilas, G. Loibl, S. Mackey, J. Martin, M. Del Mastro, L. Moebus, V. Nekljudova, V. De Placido, S. Swain, S. Untch, M. Pritchard, K.I. Bergh, J. Norton, L. Fasching, P. Harbeck, N. Untch, M. Piedbois, P. Gnant, M. Steger, G. Di Leo, A. Dolci, S. Francis, P. Larsimont, D. Nogaret, J.M. Philippson, C. Piccart-Gebhart, M.J. Linn, S. Peer, P. Tjan-Heijnen, V. Vliek, S. Mackey, J. Martin, M. Slamon, D. Bartlett, J.M. Bramwell, V.H. Chen, B.E. Chia, S.K. Gelmon, K. Goss, P.E. Levine, M.N. Parulekar, W. Pater, J.L. Pritchard, K.I. Rakovitch, E. Shepherd, L.E. Tu, D. Whelan, T. Berry, D. Broadwater, G. Cirrincione, C. Muss, H. Norton, L. Weiss, R.B. Shan, Y. Shao, Y.F. Wang, X. Xu, B. Zhao, D.B. Bartelink, H. Bijker, N. Bogaerts, J. Cardoso, F. Cufer, T. Julien, J.P. Poortmans, P.M. Rutgers, E. van de Velde, C.J. Carrasco, E. Martin, M. Segui, M.A. Blohmer, J.U. Costa, S.D. Gerber, B. Jackisch, C. Loibl, S. Nekljudova, V. von Minckwitz, G. Bruzzi, P. Giuliano, M. De laurentiis, M. De Placido, S. Del Mastro, L. Bamia, C. Fountzilas, G. Koliou, G.-. Mavroudis, D. A'Hern, R. Bliss, J. Cameron, D. Ellis, P. Kilburn, L. Morden, J. Yarnold, J.R. Sadoon, M. Tulusan, A.H. Anderson, S. Bass, G. Costantino, J. Dignam, J. Fisher, B. Geyer, C. Mamounas, E.P. Paik, S. Redmond, C. Swain, S. Wickerham, L. Wolmark, N. Del Mastro, L. Venturini, M. Bighin, C. Bruzzi, P. Del Mastro, L. Pastorino, S. Pronzato, P. Sertoli, M.R. Barlow, W. Bergh, J. Foukakis, T. Pritchard, K.I. Swain, S. Cameron, D. Albain, K. Anderson, S. Arriagada, R. Barlow, W. Bartlett, J. Bergsten-Nordstrom, E. Bliss, J. Boccardo, F. Bradley, R. Brain, E. Braybrooke, J. Carey, L. Clarke, M. Coates, A. Coleman, R. Correa, C. Costantino, J. Cuzick, J. Davidson, N. Davies, C. Davies, L. Di Leo, A. Dodwell, D. Dowsett, M. Duane, F. Ewertz, M. Forbes, J. Francis, P. Gelber, R. Gnant, M. Goldhirsch, A. Goodwin, P. Gray, R. Hayes, D. Hill, C. Ingle, J. Jagsi, R. Janni, W. Liu, Z. Loibl, S. MacKinnon, E. Mannu, G. Martin, M. McGale, P. Mukai, H. Nekljudova, V. Norton, L. Ohashi, Y. Paik, S. Pan, H. Peto, R. Piccart, M. Pierce, L. Poortmans, P. Raina, V. Ravdin, P. Rea, D. Regan, M. Robertson, J. Rutgers, E. Slamon, D. Sparano, J. Steger, G. Taylor, C. Tutt, A. Viale, G. Wang, X. Whelan, T. Wilcken, N. Wolmark, N. Wood, W. Zambetti, M. EBCTCG, (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials. Lancet, Vol.393 (10179), pp. 1440-1452.

Abubakar, M. Figueroa, J. Ali, H.R. Blows, F. Lissowska, J. Caldas, C. Easton, D.F. Sherman, M.E. Garcia-Closas, M. Dowsett, M. Pharoah, P.D. (2019). Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Modern pathology, Vol.32 (9), pp. 1244-1256.

Cocce, K.J. Jasper, J.S. Desautels, T.K. Everett, L. Wardell, S. Westerling, T. Baldi, R. Wright, T.M. Tavares, K. Yllanes, A. Bae, Y. Blitzer, J.T. Logsdon, C. Rakiec, D.P. Ruddy, D.A. Jiang, T. Broadwater, G. Hyslop, T. Hall, A. Laine, M. Phung, L. Greene, G.L. Martin, L.-. Pancholi, S. Dowsett, M. Detre, S. Marks, J.R. Crawford, G.E. Brown, M. Norris, J.D. Chang, C.-. McDonnell, D.P. (2019). The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell reports, Vol.29 (4), pp. 889-903.e10.

Haynes, B.P. Ginsburg, O. Gao, Q. Folkerd, E. Afentakis, M. Buus, R. Quang, L.H. Thi Han, P. Khoa, P.H. Dinh, N.V. To, T.V. Clemons, M. Holcombe, C. Osborne, C. Evans, A. Skene, A. Sibbering, M. Rogers, C. Laws, S. Noor, L. Smith, I.E. Dowsett, M. (2019). Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer. Npj breast cancer, Vol.5 (1).

Dowsett, M. Turner, N. (2019). Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. J clin oncol, Vol.37 (9), pp. 689-692.

Asselain, B. Barlow, W. Bartlett, J. Bergh, J. Bergsten-Nordström, E. Bliss, J. Boccardo, F. Boddington, C. Bogaerts, J. Bonadonna, G. Bradley, R. Brain, E. Braybrooke, J. Broet, P. Bryant, J. Burrett, J. Cameron, D. Clarke, M. Coates, A. Coleman, R. Coombes, R.C. Correa, C. Costantino, J. Cuzick, J. Danforth, D. Davidson, N. Davies, C. Davies, L. Di Leo, A. Dodwell, D. Dowsett, M. Duane, F. Evans, V. Ewertz, M. Fisher, B. Forbes, J. Ford, L. Gazet, J.-. Gelber, R. Gettins, L. Gianni, L. Gnant, M. Godwin, J. Goldhirsch, A. Goodwin, P. Gray, R. Hayes, D. Hill, C. Ingle, J. Jagsi, R. Jakesz, R. James, S. Janni, W. Liu, H. Liu, Z. Lohrisch, C. Loibl, S. MacKinnon, L. Makris, A. Mamounas, E. Mannu, G. Martín, M. Mathoulin, S. Mauriac, L. McGale, P. McHugh, T. Morris, P. Mukai, H. Norton, L. Ohashi, Y. Olivotto, I. Paik, S. Pan, H. Peto, R. Piccart, M. Pierce, L. Poortmans, P. Powles, T. Pritchard, K. Ragaz, J. Raina, V. Ravdin, P. Read, S. Regan, M. Robertson, J. Rutgers, E. Scholl, S. Slamon, D. Sölkner, L. Sparano, J. Steinberg, S. Sutcliffe, R. Swain, S. Taylor, C. Tutt, A. Valagussa, P. van de Velde, C. van der Hage, J. Viale, G. von Minckwitz, G. Wang, Y. Wang, Z. Wang, X. Whelan, T. Wilcken, N. Winer, E. Wolmark, N. Wood, W. Zambetti, M. Zujewski, J.A. (2018). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The lancet oncology, Vol.19 (1), pp. 27-39.

Filipits, M. Dafni, U. Gnant, M. Polydoropoulou, V. Hills, M. Kiermaier, A. de Azambuja, E. Larsimont, D. Rojo, F. Viale, G. Toi, M. Harbeck, N. Prichard, K.I. Gelber, R.D. Dinh, P. Zardavas, D. Leyland-Jones, B. Piccart-Gebhart, M.J. Dowsett, M. (2018). Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical cancer research, Vol.24 (13), pp. 3079-3086.

Tutt, A. Tovey, H. Cheang, M.C. Kernaghan, S. Kilburn, L. Gazinska, P. Owen, J. Abraham, J. Barrett, S. Barrett-Lee, P. Brown, R. Chan, S. Dowsett, M. Flanagan, J.M. Fox, L. Grigoriadis, A. Gutin, A. Harper-Wynne, C. Hatton, M.Q. Hoadley, K.A. Parikh, J. Parker, P. Perou, C.M. Roylance, R. Shah, V. Shaw, A. Smith, I.E. Timms, K.M. Wardley, A.M. Wilson, G. Gillett, C. Lanchbury, J.S. Ashworth, A. Rahman, N. Harries, M. Ellis, P. Pinder, S.E. Bliss, J.M. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat med, Vol.24 (5), pp. 628-637.  show abstract

Xiao, T. Li, W. Wang, X. Xu, H. Yang, J. Wu, Q. Huang, Y. Geradts, J. Jiang, P. Fei, T. Chi, D. Zang, C. Liao, Q. Rennhack, J. Andrechek, E. Li, N. Detre, S. Dowsett, M. Jeselsohn, R.M. Liu, X.S. Brown, M. (2018). Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy. Proc natl acad sci u s a, .  show abstract

Dodson, A. Parry, S. Ibrahim, M. Bartlett, J.M. Pinder, S. Dowsett, M. Miller, K. (2018). Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients. The journal of pathology: clinical research, Vol.4 (4), pp. 262-273.

Sestak, I. Buus, R. Cuzick, J. Dubsky, P. Kronenwett, R. Denkert, C. Ferree, S. Sgroi, D. Schnabel, C. Baehner, F.L. Mallon, E. Dowsett, M. (2018). Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Jama oncol, .  show abstract

Wolff, A.C. Hammond, M.E. Allison, K.H. Harvey, B.E. McShane, L.M. Dowsett, M. (2018). HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J oncol pract, , pp. JOP1800206-JOP1800206.

Dowsett, M. Sestak, I. Regan, M.M. Dodson, A. Viale, G. Thürlimann, B. Colleoni, M. Cuzick, J. (2018). Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J clin oncol, , pp. JCO2017764258-JCO2017764258.  show abstract

Gao, Q. López-Knowles, E. Chon U Cheang, M. Ribas, R. Sidhu, K. Evans, D. Martins, V. Dodson, A. Bliss, J.M. Smith, I. Martin, L.-. Dowsett, M. (2018). Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer. Jnci cancer spectrum, .  show abstract

Wolff, A.C. Hammond, M.E. Allison, K.H. Harvey, B.E. Mangu, P.B. Bartlett, J.M. Bilous, M. Ellis, I.O. Fitzgibbons, P. Hanna, W. Jenkins, R.B. Press, M.F. Spears, P.A. Vance, G.H. Viale, G. McShane, L.M. Dowsett, M. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J clin oncol, , pp. JCO2018778738-JCO2018778738.  show abstract

Wolff, A.C. Hammond, M.E. Allison, K.H. Harvey, B.E. Mangu, P.B. Bartlett, J.M. Bilous, M. Ellis, I.O. Fitzgibbons, P. Hanna, W. Jenkins, R.B. Press, M.F. Spears, P.A. Vance, G.H. Viale, G. McShane, L.M. Dowsett, M. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch pathol lab med, .  show abstract

Smith, I. Yardley, D. Burris, H. De Boer, R. Amadori, D. McIntyre, K. Ejlertsen, B. Gnant, M. Jonat, W. Pritchard, K.I. Dowsett, M. Hart, L. Poggio, S. Comarella, L. Salomon, H. Wamil, B. O'Shaughnessy, J. (2017). Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. J clin oncol, Vol.35 (10), pp. 1041-1048.  show abstract

Ellis, M.J. Suman, V.J. Hoog, J. Goncalves, R. Sanati, S. Creighton, C.J. DeSchryver, K. Crouch, E. Brink, A. Watson, M. Luo, J. Tao, Y. Barnes, M. Dowsett, M. Budd, G.T. Winer, E. Silverman, P. Esserman, L. Carey, L. Ma, C.X. Unzeitig, G. Pluard, T. Whitworth, P. Babiera, G. Guenther, J.M. Dayao, Z. Ota, D. Leitch, M. Olson, J.A. Allred, D.C. Hunt, K. (2017). Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J clin oncol, Vol.35 (10), pp. 1061-1069.  show abstract

Cuzick, J. Brentnall, A.R. Segal, C. Byers, H. Reuter, C. Detre, S. Lopez-Knowles, E. Sestak, I. Howell, A. Powles, T.J. Newman, W.G. Dowsett, M. (2017). Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. J clin oncol, Vol.35 (7), pp. 743-750.  show abstract

Cameron, D. Piccart-Gebhart, M.J. Gelber, R.D. Procter, M. Goldhirsch, A. de Azambuja, E. Castro, G. Untch, M. Smith, I. Gianni, L. Baselga, J. Al-Sakaff, N. Lauer, S. McFadden, E. Leyland-Jones, B. Bell, R. Dowsett, M. Jackisch, C. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The lancet, Vol.389 (10075), pp. 1195-1205.

Bartlett, J.M. Ahmed, I. Regan, M.M. Sestak, I. Mallon, E.A. Dell'Orto, P. Thurlimann, B. Seynaeve, C. Putter, H. Van de Velde, C.J. Brookes, C.L. Forbes, J.F. Viale, G. Cuzick, J. Dowsett, M. Rea, D.W. Inhibitor, T.A. (2017). HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. European journal of cancer, Vol.79, pp. 129-138.

Sheri, A. Smith, I.E. Hills, M. Jones, R.L. Johnston, S.R. Dowsett, M. (2017). Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. Breast cancer research and treatment, Vol.164 (2), pp. 395-400.

Loibl, S. Turner, N.C. Ro, J. Cristofanilli, M. Iwata, H. Im, S. Masuda, N. Loi, S. André, F. Harbeck, N. Verma, S. Folkerd, E. Puyana Theall, K. Hoffman, J. Zhang, K. Bartlett, C.H. Dowsett, M. (2017). Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA‐3 Results. The oncologist, Vol.22 (9), pp. 1028-1038.

Farland, L.V. Mu, F. Eliassen, A.H. Hankinson, S.E. Tworoger, S.S. Barbieri, R.L. Dowsett, M. Pollak, M.N. Missmer, S.A. (2017). Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. Cancer causes & control, Vol.28 (12), pp. 1441-1452.

Haynes, B.P. Ginsburg, O. Gao, Q. Folkerd, E. Afentakis, M. Quang, L.H. Han, P.T. Khoa, P.H. Dinh, N.V. To, T.V. Clemons, M. Smith, I.E. Dowsett, M. (2017). Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy. Npj breast cancer, Vol.3 (1).

Bianchini, G. Kiermaier, A. Bianchi, G.V. Im, Y.-. Pienkowski, T. Liu, M.-. Tseng, L.-. Dowsett, M. Zabaglo, L. Kirk, S. Szado, T. Eng-Wong, J. Amler, L.C. Valagussa, P. Gianni, L. (2017). Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast cancer research, Vol.19 (1).

Prat, A. Lluch, A. Turnbull, A.K. Dunbier, A.K. Calvo, L. Albanell, J. de la Haba-Rodríguez, J. Arcusa, A. Chacón, J.I. Sánchez-Rovira, P. Plazaola, A. Muñoz, M. Paré, L. Parker, J.S. Ribelles, N. Jimenez, B. Bin Aiderus, A.A. Caballero, R. Adamo, B. Dowsett, M. Carrasco, E. Martín, M. Dixon, J.M. Perou, C.M. Alba, E. (2017). A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical cancer research, Vol.23 (12), pp. 3035-3044.

Schoemaker, M.J. Jones, M.E. Allen, S. Hoare, J. Ashworth, A. Dowsett, M. Swerdlow, A.J. (2017). Childhood body size and pubertal timing in relation to adult mammographic density phenotype. Breast cancer res, Vol.19, p. 13.  show abstract

Fribbens, C. O'Leary, B. Kilburn, L. Hrebien, S. Garcia-Murillas, I. Beaney, M. Cristofanilli, M. Andre, F. Loi, S. Loibl, S. Jiang, J. Bartlett, C.H. Koehler, M. Dowsett, M. Bliss, J.M. Johnston, S.R. Turner, N.C. (2016). Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J clin oncol, Vol.34 (25), pp. 2961-2968.  show abstract

Dowsett, M. (2016). Intrinsic Subgroups or Individual Biomarkers for Predicting Outcome of Metastatic Breast Cancer?. Jama oncol, Vol.2 (10), pp. 1269-1271.

Loi, S. Dafni, U. Karlis, D. Polydoropoulou, V. Young, B.M. Willis, S. Long, B. de Azambuja, E. Sotiriou, C. Viale, G. Rüschoff, J. Piccart, M.J. Dowsett, M. Michiels, S. Leyland-Jones, B. (2016). Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. Jama oncol, Vol.2 (8), pp. 1040-1047.  show abstract

Thompson, D.J. O'Mara, T.A. Glubb, D.M. Painter, J.N. Cheng, T. Folkerd, E. Doody, D. Dennis, J. Webb, P.M. _, _. Gorman, M. Martin, L. Hodgson, S. _, _. Michailidou, K. Tyrer, J.P. Maranian, M.J. Hall, P. Czene, K. Darabi, H. Li, J. Fasching, P.A. Hein, A. Beckmann, M.W. Ekici, A.B. Dörk, T. Hillemanns, P. Dürst, M. Runnebaum, I. Zhao, H. Depreeuw, J. Schrauwen, S. Amant, F. Goode, E.L. Fridley, B.L. Dowdy, S.C. Winham, S.J. Salvesen, H.B. Trovik, J. Njolstad, T.S. Werner, H.M. Ashton, K. Proietto, T. Otton, G. Carvajal-Carmona, L. Tham, E. Liu, T. Mints, M. _, _. Scott, R.J. McEvoy, M. Attia, J. Holliday, E.G. Montgomery, G.W. Martin, N.G. Nyholt, D.R. Henders, A.K. Hopper, J.L. Traficante, N. _, _. Ruebner, M. Swerdlow, A.J. Burwinkel, B. Brenner, H. Meindl, A. Brauch, H. Lindblom, A. Lambrechts, D. Chang-Claude, J. Couch, F.J. Giles, G.G. Kristensen, V.N. Cox, A. Bolla, M.K. Wang, Q. Bojesen, S.E. Shah, M. Luben, R. Khaw, K.-. Pharoah, P.D. Dunning, A.M. Tomlinson, I. Dowsett, M. Easton, D.F. Spurdle, A.B. (2016). CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-related cancer, Vol.23 (2), pp. 77-91.  show abstract

Dodson, A. Zabaglo, L. Yeo, B. Miller, K. Smith, I. Dowsett, M. (2016). Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study. Journal of clinical pathology, Vol.69 (2), pp. 128-135.

Dunning, A.M. Michailidou, K. Kuchenbaecker, K.B. Thompson, D. French, J.D. Beesley, J. Healey, C.S. Kar, S. Pooley, K.A. Lopez-Knowles, E. Dicks, E. Barrowdale, D. Sinnott-Armstrong, N.A. Sallari, R.C. Hillman, K.M. Kaufmann, S. Sivakumaran, H. Marjaneh, M.M. Lee, J.S. Hills, M. Jarosz, M. Drury, S. Canisius, S. Bolla, M.K. Dennis, J. Wang, Q. Hopper, J.L. Southey, M.C. Broeks, A. Schmidt, M.K. Lophatananon, A. Muir, K. Beckmann, M.W. Fasching, P.A. dos-Santos-Silva, I. Peto, J. Sawyer, E.J. Tomlinson, I. Burwinkel, B. Marme, F. Guénel, P. Truong, T. Bojesen, S.E. Flyger, H. González-Neira, A. Perez, J.I. Anton-Culver, H. Eunjung, L. Arndt, V. Brenner, H. Meindl, A. Schmutzler, R.K. Brauch, H. Hamann, U. Aittomäki, K. Blomqvist, C. Ito, H. Matsuo, K. Bogdanova, N. Dörk, T. Lindblom, A. Margolin, S. Kosma, V.-. Mannermaa, A. Tseng, C.-. Wu, A.H. Lambrechts, D. Wildiers, H. Chang-Claude, J. Rudolph, A. Peterlongo, P. Radice, P. Olson, J.E. Giles, G.G. Milne, R.L. Haiman, C.A. Henderson, B.E. Goldberg, M.S. Teo, S.H. Yip, C.H. Nord, S. Borresen-Dale, A.-. Kristensen, V. Long, J. Zheng, W. Pylkäs, K. Winqvist, R. Andrulis, I.L. Knight, J.A. Devilee, P. Seynaeve, C. Figueroa, J. Sherman, M.E. Czene, K. Darabi, H. Hollestelle, A. van den Ouweland, A.M. Humphreys, K. Gao, Y.-. Shu, X.-. Cox, A. Cross, S.S. Blot, W. Cai, Q. Ghoussaini, M. Perkins, B.J. Shah, M. Choi, J.-. Kang, D. Lee, S.C. Hartman, M. Kabisch, M. Torres, D. Jakubowska, A. Lubinski, J. Brennan, P. Sangrajrang, S. Ambrosone, C.B. Toland, A.E. Shen, C.-. Wu, P.-. Orr, N. Swerdlow, A. McGuffog, L. Healey, S. Lee, A. Kapuscinski, M. John, E.M. Terry, M.B. Daly, M.B. Goldgar, D.E. Buys, S.S. Janavicius, R. Tihomirova, L. Tung, N. Dorfling, C.M. van Rensburg, E.J. Neuhausen, S.L. Ejlertsen, B. Hansen, T.V. Osorio, A. Benitez, J. Rando, R. Weitzel, J.N. Bonanni, B. Peissel, B. Manoukian, S. Papi, L. Ottini, L. Konstantopoulou, I. Apostolou, P. Garber, J. Rashid, M.U. Frost, D. Izatt, L. Ellis, S. Godwin, A.K. Arnold, N. Niederacher, D. Rhiem, K. Bogdanova-Markov, N. Sagne, C. Stoppa-Lyonnet, D. Damiola, F. Sinilnikova, O.M. Mazoyer, S. Isaacs, C. Claes, K.B. De Leeneer, K. de la Hoya, M. Caldes, T. Nevanlinna, H. Khan, S. Mensenkamp, A.R. Hooning, M.J. Rookus, M.A. Kwong, A. Olah, E. Diez, O. Brunet, J. Pujana, M.A. Gronwald, J. Huzarski, T. Barkardottir, R.B. Laframboise, R. Soucy, P. Montagna, M. Agata, S. Teixeira, M.R. Park, S.K. Lindor, N. Couch, F.J. Tischkowitz, M. Foretova, L. Vijai, J. Offit, K. Singer, C.F. Rappaport, C. Phelan, C.M. Greene, M.H. Mai, P.L. Rennert, G. Imyanitov, E.N. Hulick, P.J. Phillips, K.-. Piedmonte, M. Mulligan, A.M. Glendon, G. Bojesen, A. Thomassen, M. Caligo, M.A. Yoon, S.-. Friedman, E. Laitman, Y. Borg, A. von Wachenfeldt, A. Ehrencrona, H. Rantala, J. Olopade, O.I. Ganz, P.A. Nussbaum, R.L. Gayther, S.A. Nathanson, K.L. Domchek, S.M. Arun, B.K. Mitchell, G. Karlan, B.Y. Lester, J. Maskarinec, G. Woolcott, C. Scott, C. Stone, J. Apicella, C. Tamimi, R. Luben, R. Khaw, K.-. Helland, Å. Haakensen, V. Dowsett, M. Pharoah, P.D. Simard, J. Hall, P. García-Closas, M. Vachon, C. Chenevix-Trench, G. Antoniou, A.C. Easton, D.F. Edwards, S.L. (2016). Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature genetics, Vol.48 (4), pp. 374-386.

Sestak, I. Dowsett, M. Ferree, S. Baehner, F.L. Cuzick, J. (2016). Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast cancer research and treatment, Vol.159 (1), pp. 71-78.

Brentnall, A.R. Cuzick, J. Byers, H. Segal, C. Reuter, C. Detre, S. Sestak, I. Howell, A. Powles, T.J. Newman, W.G. Dowsett, M. (2016). Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast cancer research and treatment, Vol.158 (3), pp. 591-596.

Herrera-Abreu, M.T. Palafox, M. Asghar, U. Rivas, M.A. Cutts, R.J. Garcia-Murillas, I. Pearson, A. Guzman, M. Rodriguez, O. Grueso, J. Bellet, M. Cortes, J. Elliott, R. Pancholi, S. Lord, C.J. Baselga, J. Dowsett, M. Martin, L.-. Turner, N.C. Serra, V. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer (vol 76, pg 2301, 2016). Cancer research, Vol.76 (19), pp. 5907-5907.

Dowsett, M. Lønning, P.E. Davidson, N.E. (2016). Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. Journal of clinical oncology, Vol.34 (14), pp. 1580-1583.

Buus, R. Sestak, I. Kronenwett, R. Denkert, C. Dubsky, P. Krappmann, K. Scheer, M. Petry, C. Cuzick, J. Dowsett, M. (2016). Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the national cancer institute, Vol.108 (11), pp. djw149-djw149.

López-Knowles, E. Gao, Q. Cheang, M.C. Morden, J. Parker, J. Martin, L.-. Pinhel, I. McNeill, F. Hills, M. Detre, S. Afentakis, M. Zabaglo, L. Dodson, A. Skene, A. Holcombe, C. Robertson, J. Smith, I. Bliss, J.M. Dowsett, M. (2016). Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. Breast cancer research, Vol.18 (1).

Simigdala, N. Gao, Q. Pancholi, S. Roberg-Larsen, H. Zvelebil, M. Ribas, R. Folkerd, E. Thompson, A. Bhamra, A. Dowsett, M. Martin, L.-. (2016). Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast cancer research, Vol.18 (1).

Busana, M.C. Eng, A. Denholm, R. Dowsett, M. Vinnicombe, S. Allen, S. dos-Santos-Silva, I. (2016). Impact of type of full-field digital image on mammographic density assessment and breast cancer risk estimation: a case-control study. Breast cancer research, Vol.18 (1).

Bacci, M. Giannoni, E. Fearns, A. Ribas, R. Gao, Q. Taddei, M.L. Pintus, G. Dowsett, M. Isacke, C.M. Martin, L.-. Chiarugi, P. Morandi, A. (2016). miR-155 Drives Metabolic Reprogramming of ER + Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors. Cancer research, Vol.76 (6), pp. 1615-1626.

Herrera-Abreu, M.T. Palafox, M. Asghar, U. Rivas, M.A. Cutts, R.J. Garcia-Murillas, I. Pearson, A. Guzman, M. Rodriguez, O. Grueso, J. Bellet, M. Cortés, J. Elliott, R. Pancholi, S. Lord, C.J. Baselga, J. Dowsett, M. Martin, L.-. Turner, N.C. Serra, V. (2016). Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. Cancer research, Vol.76 (8), pp. 2301-2313.

Sestak, I. Zhang, Y. Schroeder, B.E. Schnabel, C.A. Dowsett, M. Cuzick, J. Sgroi, D. (2016). Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor–Positive Lymph Node–Negative Early-Stage Breast Cancer. Clinical cancer research, Vol.22 (20), pp. 5043-5048.

Klintman, M. Buus, R. Cheang, M.C. Sheri, A. Smith, I.E. Dowsett, M. (2016). Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease. Clinical cancer research, Vol.22 (10), pp. 2405-2416.

Abubakar, M. Howat, W.J. Daley, F. Zabaglo, L. McDuffus, L.A. Blows, F. Coulson, P. Raza Ali, H. Benitez, J. Milne, R. Brenner, H. Stegmaier, C. Mannermaa, A. Chang-Claude, J. Rudolph, A. Sinn, P. Couch, F.J. Tollenaar, R.A. Devilee, P. Figueroa, J. Sherman, M.E. Lissowska, J. Hewitt, S. Eccles, D. Hooning, M.J. Hollestelle, A. Wm Martens, J. Hm van Deurzen, C. Investigators, K. Bolla, M.K. Wang, Q. Jones, M. Schoemaker, M. Broeks, A. van Leeuwen, F.E. Van't Veer, L. Swerdlow, A.J. Orr, N. Dowsett, M. Easton, D. Schmidt, M.K. Pharoah, P.D. Garcia-Closas, M. (2016). High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. J pathol clin res, Vol.2, pp. 138-153.  show abstract

Abubakar, M. Orr, N. Daley, F. Coulson, P. Ali, H.R. Blows, F. Benitez, J. Milne, R. Brenner, H. Stegmaier, C. Mannermaa, A. Chang-Claude, J. Rudolph, A. Sinn, P. Couch, F.J. Devilee, P. Tollenaar, R.A. Seynaeve, C. Figueroa, J. Sherman, M.E. Lissowska, J. Hewitt, S. Eccles, D. Hooning, M.J. Hollestelle, A. Martens, J.W. van Deurzen, C.H. Investigators, K. Bolla, M.K. Wang, Q. Jones, M. Schoemaker, M. Wesseling, J. van Leeuwen, F.E. Van 't Veer, L. Easton, D. Swerdlow, A.J. Dowsett, M. Pharoah, P.D. Schmidt, M.K. Garcia-Closas, M. (2016). Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast cancer res, Vol.18, p. 104.  show abstract

Sheri, A. Smith, I.E. Johnston, S.R. A'Hern, R. Nerurkar, A. Jones, R.L. Hills, M. Detre, S. Pinder, S.E. Symmans, W.F. Dowsett, M. (2015). Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann oncol, Vol.26 (1), pp. 75-80.  show abstract

Leary, A. Evans, A. Johnston, S.R. A'Hern, R. Bliss, J.M. Sahoo, R. Detre, S. Haynes, B.P. Hills, M. Harper-Wynne, C. Bundred, N. Coombes, G. Smith, I. Dowsett, M. (2015). Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039). Clin cancer res, Vol.21 (13), pp. 2932-2940.  show abstract

Dowsett, M. Folkerd, E. (2015). Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. Breast cancer res treat, Vol.149 (1), pp. 1-4.  show abstract

Amoroso, V. Generali, D. Buchholz, T. Cristofanilli, M. Pedersini, R. Curigliano, G. Daidone, M.G. Di Cosimo, S. Dowsett, M. Fox, S. Harris, A.L. Makris, A. Vassalli, L. Ravelli, A. Cappelletti, M.R. Hatzis, C. Hudis, C.A. Pedrazzoli, P. Sapino, A. Semiglazov, V. Von Minckwitz, G. Simoncini, E.L. Jacobs, M.A. Barry, P. Kuhn, T. Darby, S. Hermelink, K. Symmans, F. Gennari, A. Schiavon, G. Dogliotti, L. Berruti, A. Bottini, A. (2015). International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Jnci monographs, Vol.2015 (51), pp. 90-96.

Klintman, M. Dowsett, M. (2015). Early Surrogate Markers of Treatment Activity: Where Are We Now?. Jnci monographs, Vol.2015 (51), pp. 24-28.

Ribas, R. Pancholi, S. Guest, S.K. Marangoni, E. Gao, Q. Thuleau, A. Simigdala, N. Polanska, U.M. Campbell, H. Rani, A. Liccardi, G. Johnston, S. Davies, B.R. Dowsett, M. Martin, L.-. (2015). AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. Molecular cancer therapeutics, Vol.14 (9), pp. 2035-2048.

Haynes, B.P. Viale, G. Galimberti, V. Rotmensz, N. Gibelli, B. Smith, I.E. Dowsett, M. (2015). Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast cancer res treat, Vol.149 (1), p. 311.

Mote, P.A. Gompel, A. Howe, C. Hilton, H.N. Sestak, I. Cuzick, J. Dowsett, M. Hugol, D. Forgez, P. Byth, K. Graham, J.D. Clarke, C.L. (2015). Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast cancer research and treatment, Vol.151 (2), pp. 309-318.

Polley, M.-. Leung, S.C. Gao, D. Mastropasqua, M.G. Zabaglo, L.A. Bartlett, J.M. McShane, L.M. Enos, R.A. Badve, S.S. Bane, A.L. Borgquist, S. Fineberg, S. Lin, M.-. Gown, A.M. Grabau, D. Gutierrez, C. Hugh, J.C. Moriya, T. Ohi, Y. Osborne, C.K. Penault-Llorca, F.M. Piper, T. Porter, P.L. Sakatani, T. Salgado, R. Starczynski, J. Lænkholm, A.-. Viale, G. Dowsett, M. Hayes, D.F. Nielsen, T.O. (2015). An international study to increase concordance in Ki67 scoring. Mod pathol, Vol.28 (6), pp. 778-786.  show abstract

Yeo, B. Zabaglo, L. Hills, M. Dodson, A. Smith, I. Dowsett, M. (2015). Clinical utility of the IHC4+C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. British journal of cancer, Vol.113 (3), pp. 390-395.

Gnant, M. Sestak, I. Filipits, M. Dowsett, M. Balic, M. Lopez-Knowles, E. Greil, R. Dubsky, P. Stoeger, H. Rudas, M. Jakesz, R. Ferree, S. Cowens, J.W. Nielsen, T. Schaper, C. Fesl, C. Cuzick, J. (2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Annals of oncology, Vol.26 (8), pp. 1685-1691.

Sestak, I. Cuzick, J. Dowsett, M. Lopez-Knowles, E. Filipits, M. Dubsky, P. Cowens, J.W. Ferree, S. Schaper, C. Fesl, C. Gnant, M. (2015). Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score. J clin oncol, Vol.33 (8), pp. 916-922.  show abstract

(2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The lancet, Vol.386 (10001), pp. 1341-1352.

(2015). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. The lancet, Vol.386 (10001), pp. 1353-1361.

Turnbull, A.K. Arthur, L.M. Renshaw, L. Larionov, A.A. Kay, C. Dunbier, A.K. Thomas, J.S. Dowsett, M. Sims, A.H. Dixon, J.M. (2015). Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer. Journal of clinical oncology, Vol.33 (20), pp. 2270-2278.  show abstract

Wolff, A.C. Hammond, M.E. Hicks, D.G. Allison, K.H. Bartlett, J.M. Bilous, M. Fitzgibbons, P. Hanna, W. Jenkins, R.B. Mangu, P.B. Paik, S. Perez, E.A. Press, M.F. Spears, P.A. Vance, G.H. Viale, G. Dowsett, M. McShane, L.M. Hayes, D.F. (2015). Reply to E A Rakha et al. Journal of clinical oncology, Vol.33 (11), pp. 1302-1304.

Schiavon, G. Hrebien, S. Garcia-Murillas, I. Cutts, R.J. Pearson, A. Tarazona, N. Fenwick, K. Kozarewa, I. Lopez-Knowles, E. Ribas, R. Nerurkar, A. Osin, P. Chandarlapaty, S. Martin, L.-. Dowsett, M. Smith, I.E. Turner, N.C. (2015). Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Science translational medicine, Vol.7 (313), pp. 313ra182-313ra182.

Yeo, B. Dowsett, M. (2015). Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints. Breast, Vol.24, pp. S78-S83.

Yeo, B. Dowsett, M. (2015). Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints. The breast, Vol.24, pp. S78-S83.

Engelberg, J.A. Retallack, H. Balassanian, R. Dowsett, M. Zabaglo, L. Ram, A.A. Apple, S.K. Bishop, J.W. Borowsky, A.D. Carpenter, P.M. Chen, Y.-. Datnow, B. Elson, S. Hasteh, F. Lin, F. Moatamed, N.A. Zhang, Y. Cardiff, R.D. (2015). “Score the Core” Web-based pathologist training tool improves the accuracy of breast cancer IHC4 scoring. Human pathology, Vol.46 (11), pp. 1694-1704.

López-Knowles, E. Wilkerson, P.M. Ribas, R. Anderson, H. Mackay, A. Ghazoui, Z. Rani, A. Osin, P. Nerurkar, A. Renshaw, L. Larionov, A. Miller, W.R. Dixon, J.M. Reis-Filho, J.S. Dunbier, A.K. Martin, L.-. Dowsett, M. (2015). Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer. Breast cancer research, Vol.17 (1).

Dowsett, M. Sestak, I. Buus, R. Lopez-Knowles, E. Mallon, E. Howell, A. Forbes, J.F. Buzdar, A. Cuzick, J. (2015). Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clinical cancer research, Vol.21 (12), pp. 2763-2770.

Garcia-Murillas, I. Schiavon, G. Weigelt, B. Ng, C. Hrebien, S. Cutts, R.J. Cheang, M. Osin, P. Nerurkar, A. Kozarewa, I. Garrido, J.A. Dowsett, M. Reis-Filho, J.S. Smith, I.E. Turner, N.C. (2015). Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science translational medicine, Vol.7 (302), pp. 302ra133-302ra133.

Gao, Q. Patani, N. Dunbier, A.K. Ghazoui, Z. Zvelebil, M. Martin, L.-. Dowsett, M. (2014). Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. Clin cancer res, Vol.20 (9), pp. 2485-2494.  show abstract

Patani, N. Dunbier, A.K. Anderson, H. Ghazoui, Z. Ribas, R. Anderson, E. Gao, Q. A'hern, R. Mackay, A. Lindemann, J. Wellings, R. Walker, J. Kuter, I. Martin, L.-. Dowsett, M. (2014). Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer. Clin cancer res, Vol.20 (15), pp. 3962-3973.  show abstract

Jones, M.E. Schoemaker, M.J. Rae, M. Folkerd, E.J. Dowsett, M. Ashworth, A. Swerdlow, A.J. (2014). Reproducibility of estradiol and testosterone levels in postmenopausal women over 5 years: results from the breakthrough generations study. Am j epidemiol, Vol.179 (9), pp. 1128-1133.  show abstract

Segal, C.V. Dowsett, M. (2014). Estrogen receptor mutations in breast cancer--new focus on an old target. Clin cancer res, Vol.20 (7), pp. 1724-1726.  show abstract

Hanna, W.M. Rüschoff, J. Bilous, M. Coudry, R.A. Dowsett, M. Osamura, R.Y. Penault-Llorca, F. van de Vijver, M. Viale, G. (2014). HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod pathol, Vol.27 (1), pp. 4-18.  show abstract

Schoemaker, M.J. Folkerd, E.J. Jones, M.E. Rae, M. Allen, S. Ashworth, A. Dowsett, M. Swerdlow, A.J. (2014). Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study. Br j cancer, Vol.110 (7), pp. 1898-1907.  show abstract

Wolff, A.C. Hammond, M.E. Hicks, D.G. Dowsett, M. McShane, L.M. Allison, K.H. Allred, D.C. Bartlett, J.M. Bilous, M. Fitzgibbons, P. Hanna, W. Jenkins, R.B. Mangu, P.B. Paik, S. Perez, E.A. Press, M.F. Spears, P.A. Vance, G.H. Viale, G. Hayes, D.F. American Society of Clinical Oncology, College of American Pathologists, (2014). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch pathol lab med, Vol.138 (2), pp. 241-256.  show abstract

Irshad, S. Gillett, C. Pinder, S.E. A'hern, R.P. Dowsett, M. Ellis, I.O. Bartlett, J.M. Bliss, J.M. Hanby, A. Johnston, S. Barrett-Lee, P. Ellis, P. Tutt, A. (2014). Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. Breast cancer res treat, Vol.144 (2), pp. 331-341.  show abstract

Lønning, P.E. Haynes, B.P. Dowsett, M. (2014). Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. Eur j cancer, Vol.50 (6), pp. 1055-1064.  show abstract

Yeo, B.J. Dowsett, M. Smith, I.E. Zabaglo, L. (2014). 5p * the clinical impact of using the ihc4 score: our mdt experience in a prospective series of postmenopausal women with er positive early breast cancer. Ann oncol, Vol.25 Suppl 1, p. i2.

López-Knowles, E. Segal, C.V. Gao, Q. Garcia-Murillas, I. Turner, N.C. Smith, I. Martin, L.-. Dowsett, M. (2014). Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. Breast cancer research, Vol.16 (3).

Folkerd, E.J. Lønning, P.E. Dowsett, M. (2014). Interpreting plasma estrogen levels in breast cancer: caution needed. J clin oncol, Vol.32 (14), pp. 1396-1400.

Woolf, D.K. Beresford, M. Li, S.P. Dowsett, M. Sanghera, B. Wong, W.L. Sonoda, L. Detre, S. Amin, V. Ah-See, M.-. Miles, D. Makris, A. (2014). Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br j cancer, Vol.110 (12), pp. 2847-2854.  show abstract

de Azambuja, E. Procter, M.J. van Veldhuisen, D.J. Agbor-Tarh, D. Metzger-Filho, O. Steinseifer, J. Untch, M. Smith, I.E. Gianni, L. Baselga, J. Jackisch, C. Cameron, D.A. Bell, R. Leyland-Jones, B. Dowsett, M. Gelber, R.D. Piccart-Gebhart, M.J. Suter, T.M. (2014). Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J clin oncol, Vol.32 (20), pp. 2159-2165.  show abstract

Wolff, A.C. Hammond, M.E. Hicks, D.G. Dowsett, M. Hayes, D.F. McShane, L.M. (2014). Reply to R Bhargava et al and K Lambein et al. J clin oncol, Vol.32 (17), pp. 1857-1859.

Haynes, B.P. Viale, G. Galimberti, V. Rotmensz, N. Gibelli, B. Smith, I.E. Dowsett, M. (2014). Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer. Breast cancer res treat, Vol.148 (2), pp. 327-335.  show abstract

Sestak, I. Singh, S. Cuzick, J. Blake, G.M. Patel, R. Gossiel, F. Coleman, R. Dowsett, M. Forbes, J.F. Howell, A. Eastell, R. (2014). Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet oncol, Vol.15 (13), pp. 1460-1468.  show abstract

Almendro, V. Cheng, Y.-. Randles, A. Itzkovitz, S. Marusyk, A. Ametller, E. Gonzalez-Farre, X. Muñoz, M. Russnes, H.G. Helland, A. Rye, I.H. Borresen-Dale, A.-. Maruyama, R. van Oudenaarden, A. Dowsett, M. Jones, R.L. Reis-Filho, J. Gascon, P. Gönen, M. Michor, F. Polyak, K. (2014). Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell rep, Vol.6 (3), pp. 514-527.  show abstract

Cuzick, J. Sestak, I. Forbes, J.F. Dowsett, M. Knox, J. Cawthorn, S. Saunders, C. Roche, N. Mansel, R.E. von Minckwitz, G. Bonanni, B. Palva, T. Howell, A. IBIS-II investigators, (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, Vol.383 (9922), pp. 1041-1048.  show abstract

Ribas, R. Ghazoui, Z. Gao, Q. Pancholi, S. Rani, A. Dunbier, A. Dowsett, M. Martin, L.-. (2014). Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. Breast cancer research, Vol.16 (5).

Johnson, N. Dudbridge, F. Orr, N. Gibson, L. Jones, M.E. Schoemaker, M.J. Folkerd, E.J. Haynes, B.P. Hopper, J.L. Southey, M.C. Dite, G.S. Apicella, C. Schmidt, M.K. Broeks, A. Van't Veer, L.J. Atsma, F. Muir, K. Lophatananon, A. Fasching, P.A. Beckmann, M.W. Ekici, A.B. Renner, S.P. Sawyer, E. Tomlinson, I. Kerin, M. Miller, N. Burwinkel, B. Marme, F. Schneeweiss, A. Sohn, C. Guenel, P. Truong, T. Cordina, E. Menegaux, F. Bojesen, S.E. Nordestgaard, B.G. Flyger, H. Milne, R. Zamora, M.P. Arias Perez, J.I. Benitez, J. Bernstein, L. Anton-Culver, H. Ziogas, A. Clarke Dur, C. Brenner, H. Muller, H. Arndt, V. Dieffenbach, A.K. Meindl, A. Heil, J. Bartram, C.R. Schmutzler, R.K. Brauch, H. Justenhoven, C. Ko, Y.D. Network, G. Nevanlinna, H. Muranen, T.A. Aittomaki, K. Blomqvist, C. Matsuo, K. Dork, T. Bogdanova, N.V. Antonenkova, N.N. Lindblom, A. Mannermaa, A. Kataja, V. Kosma, V.M. Hartikainen, J.M. Chenevix-Trench, G. Beesley, J. kConFab, I. Australian Ovarian Cancer Study, G. Wu, A.H. Van den Berg, D. Tseng, C.C. Lambrechts, D. Smeets, D. Neven, P. Wildiers, H. Chang-Claude, J. Rudolph, A. Nickels, S. Flesch-Janys, D. Radice, P. Peterlongo, P. Bonanni, B. Pensotti, V. Couch, F.J. Olson, J.E. Wang, X. Fredericksen, Z. Pankratz, V.S. Giles, G.G. Severi, G. Baglietto, L. Haiman, C. Simard, J. Goldberg, M.S. Labreche, F. Dumont, M. Soucy, P. Teo, S. Yip, C.H. Phuah, S.Y. Cornes, B.K. Kristensen, V.N. Grenaker Alnaes, G. Borresen-Dale, A.L. Zheng, W. Winqvist, R. Pylkas, K. Jukkola-Vuorinen, A. Grip, M. Andrulis, I.L. Knight, J.A. Glendon, G. Mulligan, A.M. Devillee, P. Figueroa, J. Chanock, S.J. Lissowska, J. Sherman, M.E. Hall, P. Schoof, N. Hooning, M. Hollestelle, A. Oldenburg, R.A. Tilanus-Linthorst, M. Liu, J. Cox, A. Brock, I.W. Reed, M.W. Cross, S.S. Blot, W. Signorello, L.B. Pharoah, P.D. Dunning, A.M. Shah, M. Kang, D. Noh, D.Y. Park, S.K. Choi, J.Y. Hartman, M. Miao, H. Lim, W.Y. Tang, A. Hamann, U. Forsti, A. Rudiger, T. Ulmer, H.U. Jakubowska, A. Lubinski, J. Jaworska-Bieniek, K. Durda, K. Sangrajrang, S. Gaborieau, V. Brennan, P. McKay, J. Slager, S. Toland, A.E. Vachon, C. Yannoukakos, D. Shen, C.Y. Yu, J.C. Huang, C.S. Hou, M.F. Gonzalez-Neira, A. Tessier, D.C. Vincent, D. Bacot, F. Luccarini, C. Dennis, J. Michailidou, K. Bolla, M.K. Wang, J. Easton, D.F. Garcia-Closas, M. Dowsett, M. Ashworth, A. Swerdlow, A.J. Peto, J. dos Santos Silva, I. Fletcher, O. (2014). Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast cancer res, Vol.16, p. R51.  show abstract

Eng, A. Gallant, Z. Shepherd, J. McCormack, V. Li, J. Dowsett, M. Vinnicombe, S. Allen, S. dos-Santos-Silva, I. (2014). Digital mammographic density and breast cancer risk: a case-control study of six alternative density assessment methods. Breast cancer research, Vol.16 (5).

Weigel, M.T. Banerjee, S. Arnedos, M. Salter, J. A'Hern, R. Dowsett, M. Martin, L.A. (2013). Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann oncol, Vol.24 (1), pp. 126-133.  show abstract

Dowsett, M. Sestak, I. Lopez-Knowles, E. Sidhu, K. Dunbier, A.K. Cowens, J.W. Ferree, S. Storhoff, J. Schaper, C. Cuzick, J. (2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J clin oncol, Vol.31 (22), pp. 2783-2790.  show abstract

Folkerd, E.J. Dixon, J.M. A'Hern, R.P. Dowsett, M. (2013). Reply to S Pauwels et al. Journal of clinical oncology, Vol.31 (4), pp. 509-510.

Wolff, A.C. Hammond, M.E. Hicks, D.G. Dowsett, M. McShane, L.M. Allison, K.H. Allred, D.C. Bartlett, J.M. Bilous, M. Fitzgibbons, P. Hanna, W. Jenkins, R.B. Mangu, P.B. Paik, S. Perez, E.A. Press, M.F. Spears, P.A. Vance, G.H. Viale, G. Hayes, D.F. American Society of Clinical Oncology, College of American Pathologists, (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J clin oncol, Vol.31 (31), pp. 3997-4013.  show abstract

Metzger-Filho, O. Procter, M. de Azambuja, E. Leyland-Jones, B. Gelber, R.D. Dowsett, M. Loi, S. Saini, K.S. Cameron, D. Untch, M. Smith, I. Gianni, L. Baselga, J. Jackisch, C. Bell, R. Sotiriou, C. Viale, G. Piccart-Gebhart, M. (2013). Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J clin oncol, Vol.31 (16), pp. 1954-1960.  show abstract

Haynes, B.P. Viale, G. Galimberti, V. Rotmensz, N. Gibelli, B. A'Hern, R. Smith, I.E. Dowsett, M. (2013). Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast cancer res treat, Vol.138 (1), pp. 157-165.  show abstract

Bao, T. Cai, L. Giles, J.T. Gould, J. Tarpinian, K. Betts, K. Medeiros, M. Jeter, S. Tait, N. Chumsri, S. Armstrong, D.K. Tan, M. Folkerd, E. Dowsett, M. Singh, H. Tkaczuk, K. Stearns, V. (2013). A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast cancer res treat, Vol.138 (1), pp. 167-174.  show abstract

Sestak, I. Dowsett, M. Zabaglo, L. Lopez-Knowles, E. Ferree, S. Cowens, J.W. Cuzick, J. (2013). Factors predicting late recurrence for estrogen receptor-positive breast cancer. J natl cancer inst, Vol.105 (19), pp. 1504-1511.  show abstract

Dowsett, M. (2013). SEX HORMONES AND BREAST CANCER RISK AND PROGNOSIS. Breast, Vol.22, pp. S5-S6.

Bartlett, J.M. A'hern, R. Piper, T. Ellis, I.O. Dowsett, M. Mallon, E.A. Cameron, D.A. Johnston, S. Bliss, J.M. Ellis, P. Barrett-Lee, P.J. (2013). Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. Breast cancer res treat, Vol.138 (3), pp. 773-781.  show abstract

Patani, N. Martin, L.-. Dowsett, M. (2013). Biomarkers for the clinical management of breast cancer: international perspective. Int j cancer, Vol.133 (1), pp. 1-13.  show abstract

Jones, M.E. Schoemaker, M. Rae, M. Folkerd, E.J. Dowsett, M. Ashworth, A. Swerdlow, A.J. (2013). Changes in estradiol and testosterone levels in postmenopausal women after changes in body mass index. J clin endocrinol metab, Vol.98 (7), pp. 2967-2974.  show abstract

Afentakis, M. Dowsett, M. Sestak, I. Salter, J. Howell, T. Buzdar, A. Forbes, J. Cuzick, J. (2013). Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast cancer res treat, Vol.140 (2), pp. 253-262.  show abstract

Martin, L.-. Dowsett, M. (2013). BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?. Cancer cell, Vol.24 (1), pp. 7-9.  show abstract

Folkerd, E. Dowsett, M. (2013). Sex hormones and breast cancer risk and prognosis. Breast, Vol.22 Suppl 2, pp. S38-S43.  show abstract

Johnston, S.R. Kilburn, L.S. Ellis, P. Dodwell, D. Cameron, D. Hayward, L. Im, Y.-. Braybrooke, J.P. Brunt, A.M. Cheung, K.-. Jyothirmayi, R. Robinson, A. Wardley, A.M. Wheatley, D. Howell, A. Coombes, G. Sergenson, N. Sin, H.-. Folkerd, E. Dowsett, M. Bliss, J.M. SoFEA investigators, (2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet oncol, Vol.14 (10), pp. 989-998.  show abstract

Key, T.J. Appleby, P.N. Reeves, G.K. Travis, R.C. Alberg, A.J. Barricarte, A. Berrino, F. Krogh, V. Sieri, S. Brinton, L.A. Dorgan, J.F. Dossus, L. Dowsett, M. Eliassen, A.H. Fortner, R.T. Hankinson, S.E. Helzlsouer, K.J. Hoffman-Bolton, J. Comstock, G.W. Kaaks, R. Kahle, L.L. Koenig, K. Zeleniuch-Jacquotte, A. Muti, P. Overvad, K. Peeters, P.H. Riboli, E. Rinaldi, S. Rollison, D.E. Stanczyk, F.Z. Trichopoulos, D. Tworoger, S.S. Tworoger, S.S. Vineis, P. (2013). Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet oncology, Vol.14 (10), pp. 1009-1019.

Sgroi, D.C. Sestak, I. Cuzick, J. Zhang, Y. Schnabel, C.A. Schroeder, B. Erlander, M.G. Dunbier, A. Sidhu, K. Lopez-Knowles, E. Goss, P.E. Dowsett, M. (2013). Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet oncology, Vol.14 (11), pp. 1067-1076.

Dowsett, M. (2013). Pathology challenges for biology-driven trials: The Ki67 experience. European journal of cancer, Vol.49, pp. S1-S2.

Zabaglo, L. Stoss, O. Rüschoff, J. Zielinski, D. Salter, J. Arfi, M. Bradbury, I. Dafni, U. Piccart-Gebhart, M. Procter, M. Dowsett, M. HERA Trial Study Team, (2013). HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. Ann oncol, Vol.24 (11), pp. 2761-2766.  show abstract

Dunbier, A.K. Ghazoui, Z. Anderson, H. Salter, J. Nerurkar, A. Osin, P. A'hern, R. Miller, W.R. Smith, I.E. Dowsett, M. (2013). Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin cancer res, Vol.19 (10), pp. 2775-2786.  show abstract

Sheri, A. Smith, I.E. A'Hern, R. Jones, R. Parton, M. Johnston, S.R. Dowsett, M. (2013). Abstract P1-08-03: Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer by IHC4 or Ki67 alone. Poster session abstracts, .

Woolf, D.K. Beresford, M. Li, S.P. Sanghera, B. Wong, W.L. Amin, V. Ah-See, M.-. Miles, D. Sonoda, L. Detre, S. Dowsett, M. Makris, A. (2013). Abstract P4-01-07: Evaluation of FLT PET-CT as an imaging biomarker of proliferation in primary breast cancer. Poster session abstracts, .

Turnbull, A.K. Arthur, L. Webber, V. Larionov, A.A. Renshaw, L. Kay, C. Dunbier, A. Dowsett, M. Sims, A.H. Dixon, J.M. (2013). Abstract PD3-2: Accurate and robust prediction of clinical response to aromatase inhibitors by two weeks of neoadjuvant breast cancer treatment. Poster discussion abstracts, .

Sestak, I. Cuzick, J. Dowsett, M. Filipits, M. Dubsky, P. Cowens, W. Ferree, S. Schaper, C. Fesl, C. Gnant, M. (2013). Abstract S6-04: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. General session abstracts, .

Polley, M.-. Leung, S.C. McShane, L.M. Gao, D. Hugh, J.C. Mastropasqua, M.G. Viale, G. Zabaglo, L.A. Penault-Llorca, F. Bartlett, J.M. Gown, A.M. Symmans, W.F. Piper, T. Mehl, E. Enos, R.A. Hayes, D.F. Dowsett, M. Nielsen, T.O. International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group, (2013). An international Ki67 reproducibility study. J natl cancer inst, Vol.105 (24), pp. 1897-1906.  show abstract

Goldhirsch, A. Gelber, R.D. Piccart-Gebhart, M.J. de Azambuja, E. Procter, M. Suter, T.M. Jackisch, C. Cameron, D. Weber, H.A. Heinzmann, D. Dal Lago, L. McFadden, E. Dowsett, M. Untch, M. Gianni, L. Bell, R. Köhne, C.-. Vindevoghel, A. Andersson, M. Brunt, A.M. Otero-Reyes, D. Song, S. Smith, I. Leyland-Jones, B. Baselga, J. Herceptin Adjuvant (HERA) Trial Study Team, (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, Vol.382 (9897), pp. 1021-1028.  show abstract

Cuzick, J. Sestak, I. Bonanni, B. Costantino, J.P. Cummings, S. DeCensi, A. Dowsett, M. Forbes, J.F. Ford, L. LaCroix, A.Z. Mershon, J. Mitlak, B.H. Powles, T. Veronesi, U. Vogel, V. Wickerham, D.L. SERM, C.B. (2013). Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, Vol.381 (9880), pp. 1827-1834.

Skippage, P. Wilkinson, L. Allen, S. Roche, N. Dowsett, M. a'Hern, R. (2013). Correlation of Age and HRT Use with Breast Density as Assessed by Quantra (TM). Breast journal, Vol.19 (1), pp. 79-86.

Patani, N. Martin, L.-. Reis-Filho, J.S. Dowsett, M. (2012). The role of caveolin-1 in human breast cancer. Breast cancer res treat, Vol.131 (1), pp. 1-15.  show abstract

Patani, N. Lambros, M.B. Natrajan, R. Dedes, K.J. Geyer, F.C. Ward, E. Martin, L.-. Dowsett, M. Reis-Filho, J.S. (2012). Non-existence of caveolin-1 gene mutations in human breast cancer. Breast cancer res treat, Vol.131 (1), pp. 307-310.  show abstract

Attard, G. Reid, A.H. Auchus, R.J. Hughes, B.A. Cassidy, A.M. Thompson, E. Oommen, N.B. Folkerd, E. Dowsett, M. Arlt, W. de Bono, J.S. (2012). Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J clin endocrinol metab, Vol.97 (2), pp. 507-516.  show abstract

Higgins, M.J. Prowell, T.M. Blackford, A.L. Byrne, C. Khouri, N.F. Slater, S.A. Jeter, S.C. Armstrong, D.K. Davidson, N.E. Emens, L.A. Fetting, J.H. Powers, P.P. Wolff, A.C. Green, H. Thibert, J.N. Rae, J.M. Folkerd, E. Dowsett, M. Blumenthal, R.S. Garber, J.E. Stearns, V. (2012). A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast cancer research and treatment, Vol.131 (3), pp. 915-924.

Johnson, N. Walker, K. Gibson, L.J. Orr, N. Folkerd, E. Haynes, B. Palles, C. Coupland, B. Schoemaker, M. Jones, M. Broderick, P. Sawyer, E. Kerin, M. Tomlinson, I.P. Zvelebil, M. Chilcott-Burns, S. Tomczyk, K. Simpson, G. Williamson, J. Hillier, S.G. Ross, G. Houlston, R.S. Swerdlow, A. Ashworth, A. Dowsett, M. Peto, J. Dos Santos Silva, I. Fletcher, O. (2012). CYP3A variation, premenopausal estrone levels, and breast cancer risk. J natl cancer inst, Vol.104 (9), pp. 657-669.  show abstract

(2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The lancet, Vol.379 (9814), pp. 432-444.

Brand, J.S. van der Schouw, Y.T. Dowsett, M. Folkerd, E. Luben, R.N. Wareham, N.J. Khaw, K.-. (2012). Testosterone, SHBG and differential white blood cell count in middle-aged and older men. Maturitas, Vol.71 (3), pp. 274-278.

Wills, S. Ravipati, A. Venuturumilli, P. Kresge, C. Folkerd, E. Dowsett, M. Hayes, D.F. Decker, D.A. (2012). Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J oncol pract, Vol.8 (3), pp. 144-148.  show abstract

Ferraldeschi, R. Arnedos, M. Hadfield, K.D. A'Hern, R. Drury, S. Wardley, A. Howell, A. Evans, D.G. Roberts, S.A. Smith, I. Newman, W.G. Dowsett, M. (2012). Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast cancer research and treatment, Vol.133 (3), pp. 1191-1198.

Balko, J.M. Cook, R.S. Vaught, D.B. Kuba, M.G. Miller, T.W. Bhola, N.E. Sanders, M.E. Granja-Ingram, N.M. Smith, J.J. Meszoely, I.M. Salter, J. Dowsett, M. Stemke-Hale, K. Gonzalez-Angulo, A.M. Mills, G.B. Pinto, J.A. Gomez, H.L. Arteaga, C.L. (2012). Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature medicine, Vol.18 (7), pp. 1052-+.

Dowsett, M. (2012). Obesity may affect response to breast cancer treatment. British journal of hospital medicine, Vol.73 (8), pp. 428-428.

Rae, J.M. Hayes, D.F. Cuzick, J. Sestak, I. Dowsett, M. (2012). Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response. Journal of the national cancer institute, Vol.104 (16), pp. 1267-1268.

Sheri, A. Dowsett, M. (2012). Developments in Ki67 and other biomarkers for treatment decision making in breast cancer. Ann oncol, Vol.23 Suppl 10, pp. x219-x227.  show abstract

Simmons, C.E. Kuchuk, I. Freedman, O.C. Colgan, T. Dodd, A. Kulhanek, K. Sheiner, J. Dranitsaris, G. Dowsett, M. Folkerd, E. Clemons, M.J. (2012). Are Estring® and Vagifem® equally effective and safe for the treatment of urogenital atrophy in breast cancer patients on aromatase inhibitor therapy?. Clin oncol (r coll radiol), Vol.24 (8), pp. e128-e129.

Varghese, J.S. Smith, P.L. Folkerd, E. Brown, J. Leyland, J. Audley, T. Warren, R.M. Dowsett, M. Easton, D.F. Thompson, D.J. (2012). The heritability of mammographic breast density and circulating sex-hormone levels: two independent breast cancer risk factors. Cancer epidemiol biomarkers prev, Vol.21 (12), pp. 2167-2175.  show abstract

Pinhel, I. Hills, M. Drury, S. Salter, J. Sumo, G. A'Hern, R. Bliss, J.M. Sestak, I. Cuzick, J. Barrett-Lee, P. Harris, A. Dowsett, M. NCRI Adjuvant Breast Cancer Trial Management Group, (2012). ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast cancer res, Vol.14 (2), p. R46.  show abstract

Motion, J. Ashcroft, L. Dowsett, M. Cuzick, J. Hickman, J. Evans, G. Eccles, D. Eeles, R. Greenhalgh, R. Affen, J. Bundred, S. Boggis, C. Sergeant, J. Fallowfield, L. Adams, J. Howell, A. (2012). Abstract P1-09-05: The RAZOR trial: a phase II prevention trial of screening plus goserilin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer. Poster session abstracts, .

Ross, G.M. Johnson, N. Orr, N. Walker, K. Gibson, L. Folkerd, E. Haynes, B. Palles, C. Coupland, B. Shoemaker, M. Jones, M. Broderick, P. Sawyer, E. Kerin, M. Tomlinson, I. Zvelebil, M. Chilcott-Burns, S. Tomczyk, K. Simpson, G. Willianson, J. Hillier, S. Houlston, R. Swerdlow, A. Ashworth, A. Dowsett, M. Peto, J. dos Santos, I. Fletcher, O. (2012). Abstract P3-08-04: Impact of CYP3A variation on estrone levels and breast cancer risk. Poster session abstracts, .

Ribas, R. Ghazoui, Z. Dowsett, M. Martin, L.-. (2012). Abstract PD01-05: Analysis of patients with ER-positive breast tumors treated with neoadjuvant aromatase inhibition identifies chemokine receptors as potential modulators of endocrine resistance. Poster discussion abstracts, .

Regan, M.M. Dafni, U. Karlis, D. Goldhirsch, A. Untch, M. Smith, I. Gianni, L. Jackisch, C. de Azambuja, E. Heinzmann, D. Cameron, D. Bell, R. Dowsett, M. Baselga, J. Leyland-Jones, B. Piccart-Gebhart, M.J. Gelber, R.D. (2012). Abstract P5-18-02: Selective Crossover in Randomized Trials of Adjuvant Trastuzumab for Breast Cancer: Coping with Success. Poster session abstracts, .

Nielsen, T.O. Polley, M.-. Leung, S.C. Mastropasqua, M.G. Zabaglo, L.A. Bartlett, J.M. Viale, G. McShane, L.M. Hayes, D.F. Dowsett, M. (2012). Abstract S4-6: An international Ki67 reproducibility study. General session abstracts, .

Goldhirsch, A. Piccart-Gebhart, M.J. Procter, M. de Azambuja, E. Weber, H.A. Untch, M. Smith, I. Gianni, L. Jackisch, C. Cameron, D. Bell, R. Dowsett, M. Gelber, R.D. Leyland-Jones, B. Baselga, J. (2012). Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. General session abstracts, .

Sgroi, D.C. Sestak, I. Zhang, Y. Erlander, M.G. Schnabel, C.A. Goss, P.E. Cuzick, J. Dowsett, M. (2012). Abstract P2-10-15: Evaluation of Prognostic and Predictive Performance of Breast Cancer Index and Its Components in Hormonal Receptor-Positive Breast Cancer Patients: A TransATAC Study. Poster session abstracts, .

Sgroi, D.C. Sestak, I. Cuzick, J. Zhang, Y. Schnabel, C.A. Erlander, M.G. Goss, P.E. Dowsett, M. (2012). Abstract S1-9: Comparative Performance of Breast Cancer Index (BCI) vs Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study. General session abstracts, .

Canon, J.L. Bergh, J. Saura, C. Oliveira, M. Houk, B. Millham, R. Barton, J. Dowsett, M. Giorgetti, C. (2012). Phase lb/II study of an oral PI3K/mTOR inhibitor plus letrozole compared with letrozole (L) in pre-operative setting in patients with Estrogen Receptor-positive, HER2-negative early breast cancer (BC): Phase lb preliminary data. Cancer research, Vol.72.

Martin, L.-. Pancholi, S. Farmer, I. Guest, S. Ribas, R. Weigel, M.T. Thornhill, A.M. Ghazoui, Z. A'Hern, R. Evans, D.B. Lane, H.A. Johnston, S.R. Dowsett, M. (2012). Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast cancer res, Vol.14 (5), p. R132.  show abstract

Weigel, M.T. Ghazoui, Z. Dunbier, A. Pancholi, S. Dowsett, M. Martin, L.-. (2012). Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast cancer res, Vol.14 (3), p. R78.  show abstract

Folkerd, E.J. Dixon, J.M. Renshaw, L. A'Hern, R.P. Dowsett, M. (2012). Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J clin oncol, Vol.30 (24), pp. 2977-2980.  show abstract

Rae, J.M. Drury, S. Hayes, D.F. Stearns, V. Thibert, J.N. Haynes, B.P. Salter, J. Sestak, I. Cuzick, J. Dowsett, M. ATAC trialists, (2012). CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J natl cancer inst, Vol.104 (6), pp. 452-460.  show abstract

Barton, S. Zabaglo, L. A'Hern, R. Turner, N. Ferguson, T. O'Neill, S. Hills, M. Smith, I. Dowsett, M. (2012). Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br j cancer, Vol.106 (11), pp. 1760-1765.  show abstract

Prescott, J. Thompson, D.J. Kraft, P. Chanock, S.J. Audley, T. Brown, J. Leyland, J. Folkerd, E. Doody, D. Hankinson, S.E. Hunter, D.J. Jacobs, K.B. Dowsett, M. Cox, D.G. Easton, D.F. De Vivo, I. (2012). Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women. Plos one, Vol.7 (6), p. e37815.  show abstract

Lundgren, K. Brown, M. Pineda, S. Cuzick, J. Salter, J. Zabaglo, L. Howell, A. Dowsett, M. Landberg, G. Investigators, T. (2012). Effects of cyclin D-1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast cancer research, Vol.14 (2).

Folkerd, E.J. Dowsett, M. (2011). Influence of Sex Hormones on Melanoma Reply. Journal of clinical oncology, Vol.29 (4), pp. E96-1.

Dunbier, A.K. Anderson, H. Ghazoui, Z. Lopez-Knowles, E. Pancholi, S. Ribas, R. Drury, S. Sidhu, K. Leary, A. Martin, L.-. Dowsett, M. (2011). ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25 1. Plos genetics, Vol.7 (4), p. 11.

Ghazoui, Z. Buffa, F.M. Dunbier, A.K. Anderson, H. Dexter, T. Detre, S. Salter, J. Smith, I.E. Harris, A.L. Dowsett, M. (2011). Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor-Treated ER-Positive Breast Cancer. Clinical cancer research, Vol.17 (9), pp. 3005-8.

Tolhurst, R.S. Thomas, R.S. Kyle, F.J. Patel, H. Periyasamy, M. Photiou, A. Thiruchelvam, P.T. Lai, C.-. Al-Sabbagh, M. Fisher, R.A. Barry, S. Crnogorac-Jurcevic, T. Martin, L.-. Dowsett, M. Coombes, R.C. Kamalati, T. Ali, S. Buluwela, L. (2011). Transient over-expression of estrogen receptor-alpha in breast cancer cells promotes cell survival and estrogen-independent growth. Breast cancer research and treatment, Vol.128 (2), pp. 357-12.

Dunbier, A.K. Anderson, H. Ghazoui, Z. Salter, J. Parker, J.S. Perou, C.M. Smith, I.E. Dowsett, M. (2011). Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids, Vol.76 (8), pp. 736-5.

Wolff, A.C. Dowsett, M. (2011). Estrogen Receptor: A Never Ending Story?. Journal of clinical oncology, Vol.29 (22), pp. 2955-5.

Lønning, P.E. Haynes, B.P. Straume, A.H. Dunbier, A. Helle, H. Knappskog, S. Dowsett, M. (2011). Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clin cancer res, Vol.17 (15), pp. 4948-4958.  show abstract

Dowsett, M. Lonning, P.E. (2011). Special Issue 10th International Aromatase Conference Proceedings, September 2010 Preface. Steroids, Vol.76 (8), pp. 729-1.

Lonning, P.E. Haynes, B.P. Straume, A.H. Dunbier, A. Helle, H. Knappskog, S. Dowsett, M. (2011). Recent data on intratumor estrogens in breast cancer. Steroids, Vol.76 (8), pp. 786-6.

Stanway, S.J. Palmieri, C. Stanczyk, F.Z. Folkerd, E.J. Dowsett, M. Ward, R. Coombes, R.C. Reed, M.J. Purohit, A. (2011). Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer. Anticancer research, Vol.31 (4), pp. 1367-6.

Dowsett, M. (2011). Cytotoxic drugs: The endocrine part of the story. Breast, Vol.20, pp. S5-1.

Brand, J.S. Wareham, N.J. Dowsett, M. Folkerd, E. van der Schouw, Y.T. Luben, R.N. Khaw, K.-. (2011). Associations of endogenous testosterone and SHBG with glycated haemoglobin in middle-aged and older men. Clinical endocrinology, Vol.74 (5), pp. 572-7.

Miller, T.W. Balko, J.M. Ghazoui, Z. Dunbier, A. Anderson, H. Dowsett, M. Gonzalez-Angulo, A.M. Mills, G.B. Miller, W.R. Wu, H. Shyr, Y. Arteaga, C.L. (2011). A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. Clinical cancer research, Vol.17 (7), pp. 2024-11.

Cuzick, J. Sestak, I. Baum, M. Buzdar, A. Howell, A. Dowsett, M. Forbes, J.F. (2011). 10-year analysis of the ATAC trial: wrong conclusion? Reply. Lancet oncology, Vol.12 (3), pp. 217-1.

Sikora, M.J. Thibert, J.N. Salter, J. Dowsett, M. Johnson, M.D. Rae, J.M. (2011). High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues. Pharmacogenomics journal, Vol.11 (5), pp. 348-11.

Miller, T.W. Balko, J.M. Fox, E.M. Ghazoui, Z. Dunbier, A. Anderson, H. Dowsett, M. Jiang, A. Smith, R.A. Maira, S.-. Manning, H.C. Gonzalez-Angulo, A.M. Mills, G.B. Higham, C. Chanthaphaychith, S. Kuba, M.G. Miller, W.R. Shyr, Y. Arteaga, C.L. (2011). ER alpha-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. Cancer discovery, Vol.1 (4), pp. 338-14.

Jones, R.L. Rojo, F. A'Hern, R. Villena, N. Salter, J. Corominas, J.M. Servitja, S. Smith, I.E. Rovira, A. Reis-Filho, J.S. Dowsett, M. Albanell, J. (2011). Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J clin pathol, Vol.64 (2), pp. 130-135.  show abstract

Dunbier, A.K. Martin, L.-. Dowsett, M. (2011). New and translational perspectives of oestrogen deprivation in breast cancer. Mol cell endocrinol, Vol.340 (2), pp. 137-141.  show abstract

Stanway, S.J. Palmieri, C. Stanczyk, F.Z. Folkerd, E.J. Dowsett, M. Ward, R. Coombes, R.C. Reed, M.J. Purohit, A. (2011). Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. Anticancer research, Vol.31 (4), pp. 1367-1372.  show abstract

Martin, L.-. Ghazoui, Z. Weigel, M.T. Pancholi, S. Dunbier, A. Johnston, S. Dowsett, M. (2011). An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition. Steroids, Vol.76 (8), pp. 772-776.  show abstract

Dowsett, M. Salter, J. Zabaglo, L. Mallon, E. Howell, A. Buzdar, A.U. Forbes, J. Pineda, S. Cuzick, J. (2011). Predictive algorithms for adjuvant therapy: TransATAC. Steroids, Vol.76 (8), pp. 777-780.  show abstract

Anderson, H. Hills, M. Zabaglo, L. A'hern, R. Leary, A.F. Haynes, B.P. Smith, I.E. Dowsett, M. (2011). Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Ann oncol, Vol.22 (8), pp. 1770-1776.  show abstract

Brand, J.S. Chan, M.-. Dowsett, M. Folkerd, E. Wareham, N.J. Luben, R.N. van der Schouw, Y.T. Khaw, K.-. (2011). Cigarette smoking and endogenous sex hormones in postmenopausal women. J clin endocrinol metab, Vol.96 (10), pp. 3184-3192.  show abstract

Drury, S.C. Detre, S. Leary, A. Salter, J. Reis-Filho, J. Barbashina, V. Marchio, C. Lopez-Knowles, E. Ghazoui, Z. Habben, K. Arbogast, S. Johnston, S. Dowsett, M. (2011). Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr relat cancer, Vol.18 (5), pp. 565-577.  show abstract

Ring, A. Sestak, I. Baum, M. Howell, A. Buzdar, A. Dowsett, M. Forbes, J.F. Cuzick, J. (2011). Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial. J clin oncol, Vol.29 (32), pp. 4266-4272.  show abstract

Cuzick, J. Dowsett, M. Pineda, S. Wale, C. Salter, J. Quinn, E. Zabaglo, L. Mallon, E. Green, A.R. Ellis, I.O. Howell, A. Buzdar, A.U. Forbes, J.F. (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J clin oncol, Vol.29 (32), pp. 4273-4278.  show abstract

Sheri, A. Dowsett, M. (2011). Predicting response to cytotoxic drugs--the endocrine part of the story. Breast, Vol.20 Suppl 3, pp. S28-S30.  show abstract

Prowell, T.M. Blackford, A.L. Byrne, C. Khouri, N.F. Dowsett, M. Folkerd, E. Tarpinian, K.S. Powers, P.P. Wright, L.A. Donehower, M.G. Jeter, S.C. Armstrong, D.K. Emens, L.A. Fetting, J.H. Wolff, A.C. Garrett-Mayer, E. Skaar, T.C. Davidson, N.E. Stearns, V. (2011). Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer prev res (phila), Vol.4 (12), pp. 1993-2001.  show abstract

Guest, S.K. Pancholi, S. Patani, N. Dowsett, M. Johnston, S.R. Martin, L.-. (2011). PD01-03: Src Is a Potential Therapeutic Target in Endocrine Resistant Breast Cancer Exhibiting Low Estrogen Receptor (ER)-Mediated Transactivation. Poster discussion abstracts, .

Bao, T. Tarpinian, K. Medeiros, M. Gould, J. Jeter, S. Cai, L. Tait, N. Shetty, J. Lewis, J. Gitten, L. Betts, K. Hoffman, A. Feigenberg, S. Chumsri, S. Armstronge, D.K. Bardia, A. Tan, M. Stebbing, J. Folkerd, E. Dowsett, M. Singh, H. Tkaczuk, K. Stearns, V. (2011). P4-12-13: A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors: First Interim Analysis. Poster session abstracts, .

Weigel, M.T. Banerjee, S. A'Hern, R. Arnedos, M. Ghazoui, Z. Dunbier, A.K. Dowsett, M. Martin, L.-. (2011). P4-01-01: Preclinical and Clinical Studies of Estrogen Deprivation Support the PDGF/Abl Pathway as a Novel Therapeutic Target for Overcoming Resistance. Poster session abstracts, .

Haynes, B.P. Viale, B. A'Hern, R. Smith, I.E. Dowsett, M. Galimberti, V. Rotmensz, N. Gibelli, B. (2011). S6-6: Expression of Key Estrogen-Regulated Genes (ERGs) Differ Substantially across the Menstrual Cycle in ER+ Breast Tumours. General session abstracts, .

Rae, J.M. Sestak, I. Henry, N.L. Drury, S. Hayes, D.F. Thibert, J.N. Lopez-Knowles, E. Salter, J. Pineda, S. Cuzick, J. Dowsett, M. (2011). P1-06-02: Correlation between Gene Variants in CYP19 (Aromatase) and TCL1A with Disease and Tolerability Endpoints in the ATAC Trial. Poster session abstracts, .

Dowsett, M. Lopez-Knowles, E. Sidhu, K. Pineda, S. Cowens, J.W. Ferree, S. Storhoff, J. Schaper, C. Cuzick, J. (2011). S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study. General session abstracts, .

Metzger, O. Procter, M. de, A.E. Viale, G. Leyland-Jones, B. Dowsett, M. Gelber, R. Gresko, E. Loi, S. Sotiriou, C. Piccart, M. (2011). P2-18-01: The Magnitude of Trastuzumab Benefit in HER2−Positive (HER2+) Lobular Breast Carcinoma (BC): Results of a HERA Trial Sub-Group Analysis. Poster session abstracts, .

Balko, J.M. Cook, R.S. Kuba, M.G. Miller, T.W. Bhola, N.E. Sanders, M.E. Meszoely, I.M. Dowsett, M. Gomez, H. Arteaga, C.L. (2011). Inhibition of MEK/ERK- and JNK-Dependent Expression of Interleukin-6 and Interleukin-8 Targets Basal-Like Breast Cancer Stem Cells. Cancer research, Vol.71.

Wang, X. Saso, H. Iwamoto, T. Pusztai, L. Gong, Y. Woodward, W.A. Reuben, J.M. Hortobagyi, G.N. Ueno, N.T. (2011). P2-02-01: A Novel Inflammatory Breast Cancer-Specific Oncogene, Tazarotene-Induced Gene 1, Promotes Tumorigenicity and Invasiveness through the Receptor Tyrosine Kinase Axl. Poster session abstracts, .

Sestak, I. Cuzick, J. Dowsett, M. Salter, J. Quinn, E. Zabaglo, L. Howell, A. Buzdar, A. Forbes, J. (2011). P2-12-09: Prediction of Residual Risk of Recurrence after 5 Years of Follow-Up by Clinicopathologic Variables and 4 IHC Markers: A TransATAC Study. Poster session abstracts, .

Dowsett, M. Nielsen, T.O. A'Hern, R. Bartlett, J. Coombes, R.C. Cuzick, J. Ellis, M. Henry, N.L. Hugh, J.C. Lively, T. McShane, L. Paik, S. Penault-Llorca, F. Prudkin, L. Regan, M. Salter, J. Sotiriou, C. Smith, I.E. Viale, G. Zujewski, J.A. Hayes, D.F. International Ki-67 in Breast Cancer Working Group, (2011). Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J natl cancer inst, Vol.103 (22), pp. 1656-1664.  show abstract

Marchiò, C. Dowsett, M. Reis-Filho, J.S. (2011). Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. Bmc med, Vol.9, p. 41.  show abstract

Mackay, A. Weigelt, B. Grigoriadis, A. Kreike, B. Natrajan, R. A'Hern, R. Tan, D.S. Dowsett, M. Ashworth, A. Reis-Filho, J.S. (2011). Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J natl cancer inst, Vol.103 (8), pp. 662-673.  show abstract

Dowsett, M. Smith, I.E. (2011). Presurgical Progesterone in Early Breast Cancer: So Much for So Little?. Journal of clinical oncology, Vol.29 (21), pp. 2839-3.

Basu, B. Ang, J.E. Crawley, D. Folkerd, E. Sarker, D. Blanco-Codesido, M. Moran, K. Wan, S. Dobbs, N. Raynaud, F. Johnston, S.R. Dowsett, M. Tutt, A.N. Spicer, J.F. Swanton, C. De Bono, J.S. (2011). Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor-(ER) or androgen receptor (AR)-positive advanced breast carcinoma resistant to standard endocrine therapies. Journal of clinical oncology, Vol.29 (15).

Guerrero-Zotano, A. Gavila, J. Folkerd, E. Ortiz, B. Labrador, T. Martinez, F. Garcia, A. Climent, M.A. Guillem, V. Dowsett, M. Ruiz, A. (2011). Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays. Journal of clinical oncology, Vol.29 (15).

Arnedos, M. Ferraldeschi, R. A'Hern, R. Hadfield, K. Roberts, S. Drury, S. Howell, A. Evans, D.G. Wardley, A.M. Smith, I.E. Newman, W.G. Dowsett, M. (2011). Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients. Journal of clinical oncology, Vol.29 (15).

Sestak, I. Harvie, M. Howell, A. Forbes, J.F. Dowsett, M. Cuzick, J.M. (2011). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. J clin oncol, Vol.29 (27_suppl), p. 165.  show abstract

Basu, B. Ang, J.E. Crawley, D. Folkerd, E. Sarker, D. Blanco-Codesido, M. Moran, K. Wan, S. Dobbs, N. Raynaud, F. Johnston, S.R. Dowsett, M. Tutt, A.N. Spicer, J.F. Swanton, C. De Bono, J.S. (2011). Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies. J clin oncol, Vol.29 (15_suppl), p. 2525.  show abstract

Balko, J.M. Cook, R.S. Miller, T.W. Bhola, N.E. Sanders, M. Granja-Ingram, N.M. Sanchez, V. Meszoely, I.M. Salter, J. Dowsett, M. Stemke-Hale, K. Gonzalez-Angulo, A.M. Mills, G.B. Arteaga, C.L. (2011). Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). J clin oncol, Vol.29 (15_suppl), p. 10509.  show abstract

Smith, I.E. Johnson, L. Dowsett, M. Robertson, J.F. Robison, L.E. Kokan, J.S. Evans, A.A. Holcombe, C. Horgan, K. Skene, A. Prasad, R. Absar, M.S. Vidya, R. Bundred, N.J. Harding-Mackean, C. Wheatley, D.A. Kissin, M.W. Pinhel, I.F. Kilburn, L.S. Bliss, J.M. POETIC Trialists, (2011). Trial of perioperative endocrine therapy: Individualizing care (POETIC). J clin oncol, Vol.29 (15_suppl), p. TPS117.  show abstract

Arnedos, M. Ferraldeschi, R. A'Hern, R. Hadfield, K. Roberts, S. Drury, S. Howell, A. Evans, D.G. Wardley, A.M. Smith, I.E. Newman, W.G. Dowsett, M. (2011). Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients. J clin oncol, Vol.29 (15_suppl), p. 608.  show abstract

Guerrero-Zotano, A. Gavila, J. Folkerd, E. Ortiz, B. Labrador, T. Martinez, F. Garcia, A. Climent, M.A. Guillem, V. Dowsett, M. Ruiz, A. (2011). Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays. J clin oncol, Vol.29 (15_suppl), p. 521.  show abstract

Sestak, I. Harvie, M. Howell, A. Forbes, J.F. Dowsett, M. Cuzick, J.M. (2011). Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with breast cancer or at high risk of developing it. Journal of clinical oncology, Vol.29 (27).

Tang, G. Cuzick, J. Costantino, J.P. Dowsett, M. Forbes, J.F. Crager, M. Mamounas, E.P. Shak, S. Wolmark, N. (2011). Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J clin oncol, Vol.29 (33), pp. 4365-4372.  show abstract

Key, T.J. Appleby, P.N. Reeves, G.K. Roddam, A.W. Helzlsouer, K.J. Alberg, A.J. Rollison, D.E. Dorgan, J.F. Brinton, L.A. Overvad, K. Kaaks, R. Trichopoulou, A. Clavel-Chapelon, F. Panico, S. Duell, E.J. Peeters, P.H. Rinaldi, S. Riboli, E. Fentiman, I.S. Dowsett, M. Manjer, J. Lenner, P. Hallmans, G. Baglietto, L. English, D.R. Giles, G.G. Hopper, J.L. Severi, G. Morris, H.A. Koenig, K. Zeleniuch-Jacquotte, A. Arslan, A.A. Toniolo, P. Shore, R.E. Krogh, V. Micheli, A. Berrino, F. Muti, P. Barrett-Connor, E. Laughlin, G.A. Kabuto, M. Akiba, S. Stevens, R.G. Neriishi, K. Land, C.E. Cauley, J.A. Lui, L.Y. Cummings, S.R. Gunter, M.J. Rohan, T.E. Strickler, H.D. (2011). Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. British journal of cancer, Vol.105 (5), pp. 709-14.

Dowsett, M. Smith, I. Robertson, J. Robison, L. Pinhel, I. Johnson, L. Salter, J. Dunbier, A. Anderson, H. Ghazoui, Z. Skene, T. Evans, A. A'Hern, R. Iskender, A. Wilcox, M. Bliss, J. (2011). Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. J natl cancer inst monogr, Vol.2011 (43), pp. 120-123.  show abstract

Early Breast Cancer Trialists' Collaborative, G. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, Vol.378 (9793), pp. 771-784.  show abstract

Weigelt, B. Mackay, A. Natrajan, R. Tan, D.S. Dowsett, M. Ashworth, A. Reis-Filho, J.S. (2010). The importance of gene-centring microarray data Reply. Lancet oncology, Vol.11 (8), pp. 720-2.

Jones, R.L. Salter, J. A'Hern, R. Nerurkar, A. Parton, M. Reis-Filho, J.S. Smith, I.E. Dowsett, M. (2010). Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast cancer res treat, Vol.119 (2), pp. 315-323.  show abstract

Dunbier, A.K. Anderson, H. Ghazoui, Z. Folkerd, E.J. A'hern, R. Crowder, R.J. Hoog, J. Smith, I.E. Osin, P. Nerurkar, A. Parker, J.S. Perou, C.M. Ellis, M.J. Dowsett, M. (2010). Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J clin oncol, Vol.28 (7), pp. 1161-1167.  show abstract

Leary, A.F. Drury, S. Detre, S. Pancholi, S. Lykkesfeldt, A.E. Martin, L.-. Dowsett, M. Johnston, S.R. (2010). Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin cancer res, Vol.16 (5), pp. 1486-1497.  show abstract

Cheung, K.L. Agrawal, A. Folkerd, E. Dowsett, M. Robertson, J.F. Winterbottom, L. (2010). Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. European journal of cancer, Vol.46 (16), pp. 2936-7.

Pinhel, I.F. MacNeill, F.A. Hills, M.J. Salter, J. Detre, S. A'Hern, R. Nerurkar, A. Osin, P. Smith, I.E. Dowsett, M. (2010). Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast cancer research, Vol.12 (5), p. 7.

Cuzick, J. Sestak, I. Baum, M. Buzdar, A. Howell, A. Dowsett, M. Forbes, J.F. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet oncology, Vol.11 (12), pp. 1135-7.

Dowsett, M. Pineda, S. Cuzick, J. (2010). What Is the Value of the 21 Gene Recurrence Score in HER2-Negative Patients? Reply. Journal of clinical oncology, Vol.28 (31), pp. E648-1.

Hammond, M.E. Hayes, D.F. Dowsett, M. Allred, D.C. Hagerty, K.L. Badve, S. Fitzgibbons, P.L. Francis, G. Goldstein, N.S. Hayes, M. Hicks, D.G. Lester, S. Love, R. Mangu, P.B. McShane, L. Miller, K. Osborne, C.K. Paik, S. Perlmutter, J. Rhodes, A. Sasano, H. Schwartz, J.N. Sweep, F.C. Taube, S. Torlakovic, E.E. Valenstein, P. Viale, G. Visscher, D. Wheeler, T. Williams, R.B. Wittliff, J.L. Wolff, A.C. (2010). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Archives of pathology & laboratory medicine, Vol.134 (7), pp. E48-25.

Hammond, M.E. Hayes, D.F. Dowsett, M. Allred, D.C. Hagerty, K.L. Badve, S. Fitzgibbons, P.L. Francis, G. Goldstein, N.S. Hayes, M. Hicks, D.G. Lester, S. Love, R. Mangu, P.B. McShane, L. Miller, K. Osborne, C.K. Paik, S. Perlmutter, J. Rhodes, A. Sasano, H. Schwartz, J.N. Sweep, F.C. Taube, S. Torlakovic, E.E. Valenstein, P. Viale, G. Visscher, D. Wheeler, T. Williams, R.B. Wittliff, J.L. Wolff, A.C. (2010). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of pathology & laboratory medicine, Vol.134 (6), pp. 907-16.

Hammond, M.E. Hayes, D.F. Dowsett, M. Allred, D.C. Hagerty, K.L. Badve, S. Fitzgibbons, P.L. Francis, G. Goldstein, N.S. Hayes, M. Hicks, D.G. Lester, S. Love, R. Mangu, P.B. McShane, L. Miller, K. Osborne, C.K. Paik, S. Perlmutter, J. Rhodes, A. Sasano, H. Schwartz, J.N. Sweep, F.C. Taube, S. Torlakovic, E.E. Valenstein, P. Viale, G. Visscher, D. Wheeler, T. Williams, R.B. Wittliff, J.L. Wolff, A.C. (2010). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of clinical oncology, Vol.28 (16), pp. 2784-12.

Freedman, O.C. Amir, E. Hanna, W. Kahn, H. O'Malley, F. Dranitsaris, G. Cole, D.E. Verma, S. Folkerd, E. Dowsett, M. Clemons, M. (2010). A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast cancer research and treatment, Vol.119 (1), pp. 155-7.

Weigelt, B. Mackay, A. A'hern, R. Natrajan, R. Tan, D.S. Dowsett, M. Ashworth, A. Reis-Filho, J.S. (2010). Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet oncol, Vol.11 (4), pp. 339-349.  show abstract

Drury, S. Salter, J. Baehner, F.L. Shak, S. Dowsett, M. (2010). Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study. J clin pathol, Vol.63 (6), pp. 513-517.  show abstract

Weigelt, B. Mackay, A. Natrajan, R. Tan, D.S. Dowsett, M. Ashworth, A. Reis-Filho, J.S. (2010). The importance of gene-centring microarray data – Authors' reply. The lancet oncology, Vol.11 (8), pp. 720-721.

Zabaglo, L. Salter, J. Anderson, H. Quinn, E. Hills, M. Detre, S. A'Hern, R. Dowsett, M. (2010). Comparative validation of the SP6 antibody to Ki67 in breast cancer. J clin pathol, Vol.63 (9), pp. 800-804.  show abstract

Martin, L.-. Davies, G.L. Weigel, M.T. Betambeau, N. Hills, M.J. Salter, J. Walsh, G. A'Hern, R. Dowsett, M. (2010). Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast cancer res treat, Vol.123 (3), pp. 829-836.  show abstract

Folkerd, E.J. Dowsett, M. (2010). Influence of Sex Hormones on Cancer Progression. Journal of clinical oncology, Vol.28 (26), pp. 4038-7.

Folkerd, E.J. Dowsett, M. (2010). Influence of sex hormones on cancer progression. J clin oncol, Vol.28 (26), pp. 4038-4044.  show abstract

Dowsett, M. Cuzick, J. Wale, C. Forbes, J. Mallon, E.A. Salter, J. Quinn, E. Dunbier, A. Baum, M. Buzdar, A. Howell, A. Bugarini, R. Baehner, F.L. Shak, S. (2010). Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J clin oncol, Vol.28 (11), pp. 1829-1834.  show abstract

Dowsett, M. (2010). Absolute Benefits of Aromatase Inhibitors in Adjuvant Treatment of Breast Cancer: Should We Know More? Reply to B Seruga et al. Journal of clinical oncology, Vol.28 (20), pp. E348-1.

Bonelli, M.A. Fumarola, C. Alfieri, R.R. La Monica, S. Cavazzoni, A. Galetti, M. Gatti, R. Belletti, S. Harris, A.L. Fox, S.B. Evans, D.B. Dowsett, M. Martin, L.-. Bottini, A. Generali, D. Petronini, P.G. (2010). Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast cancer res treat, Vol.124 (1), pp. 79-88.  show abstract

Weigel, M.T. Dowsett, M. (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr relat cancer, Vol.17 (4), pp. R245-R262.  show abstract

Evans, A.H. Pancholi, S. Farmer, I. Thornhill, A. Evans, D.B. Johnston, S.R. Dowsett, M. Martin, L.-. (2010). EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br j cancer, Vol.102 (8), pp. 1235-1243.  show abstract

Banerjee, S. A'Hern, R. Detre, S. Littlewood-Evans, A.J. Evans, D.B. Dowsett, M. Martin, L.-. (2010). Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo. Clinical cancer research, Vol.16 (16), pp. 4178-10.

Haynes, B.P. Straume, A.H. Geisler, J. A'Hern, R. Helle, H. Smith, I.E. Lønning, P.E. Dowsett, M. (2010). Intratumoral estrogen disposition in breast cancer. Clin cancer res, Vol.16 (6), pp. 1790-1801.  show abstract

Banerjee, S. A'Hern, R. Detre, S. Littlewood-Evans, A.J. Evans, D.B. Dowsett, M. Martin, L.-. (2010). Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin cancer res, Vol.16 (16), pp. 4178-4187.  show abstract

Graeser, M. McCarthy, A. Lord, C.J. Savage, K. Hills, M. Salter, J. Orr, N. Parton, M. Smith, I.E. Reis-Filho, J.S. Dowsett, M. Ashworth, A. Turner, N.C. (2010). A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin cancer res, Vol.16 (24), pp. 6159-6168.  show abstract

Leary, A.F. Martin, L.-. Thornhill, A. Dowsett, M. Johnston, S.R. (2010). Abstract P3-14-03: Combining or Sequencing Targeted Therapies in ER+/HER2 Amplified Breast Cancer (BC):In VitroandIn VivoStudies of Letrozole and Lapatinib in an ER+/HER2+ Aromatase-Transfected BC Model. Poster session abstracts, .

Walker, K. Johnson, N. Palles, C. Folkerd, E. Hillier, S.G. Moss, S. Gibson, L. Dowsett, M. Peto, J. dos Santos Silva, I. Fletcher, O. (2010). Abstract P3-12-02: Polymorphisms, Endogenous Hormone Levels and Breast Cancer Risk in Premenopausal Women. Poster session abstracts, .

Balko, J.M. Sanders, M.E. Granja-Ingram, N.M. Sanchez, V. Meszoely, I.M. Salter, J. Dowsett, M. Arteaga, C.L. (2010). Abstract P6-04-05: Digital Quantification of Post-Neoadjuvant Chemotherapy Breast Tumor RNA Reveals a Basal-Derived Gene Signature Associated with Post-Treatment Ki67. Poster session abstracts, .

Dunbier, A.K. Ghazoui, Z. Anderson, H. Smith, I.E. Dowsett, M. (2010). Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response. General session abstracts, .

Ghazoui, Z. Anderson, H. Dunbier, A. Anderson, E. Lindemann, J. Wellings, B. Walker, J. Kuter, I. Dowsett, M. (2010). Abstract P1-12-02: Transcriptional Changes Induced by Anastrozole and Fulvestrant Treatment in ER-Positive Breast Cancers. Poster session abstracts, .

Rae, J.M. Drury, S. Hayes, D.F. Stearns, V. Thibert, J.N. Haynes, B.P. Salter, J. Pineda, S. Cuzick, J. Dowsett, M. (2010). Abstract S1-7: Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enymes with Primary Endpoints in the ATAC Trial. General session abstracts, .

Ring, A.E. Sestak, I. Baum, M. Howell, A. Buzdar, A. Dowsett, M. Forbes, J.F. Cuzick, J. (2010). Abstract P5-13-03: The Influences of Co-Morbidities and Age on Risk of Death without Recurrence: A Retrospective Analysis of the ATAC Trial. Poster session abstracts, .

Zabaglo, L. Stoss, O. Rueschoff, J. Zielinski, D. Salter, J. Bradbury, I. Arfi, M. Dafni, O. Procter, M. Dowsett, M. (2010). Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience. Poster discussion abstracts, .

Plaza-Menacho, I. Morandi, A. Robertson, D. Pancholi, S. Drury, S. Dowsett, M. Martin, L.-. Isacke, C.M. (2010). Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene, Vol.29 (33), pp. 4648-4657.  show abstract

Dowsett, M. Cuzick, J. Ingle, J. Coates, A. Forbes, J. Bliss, J. Buyse, M. Baum, M. Buzdar, A. Colleoni, M. Coombes, C. Snowdon, C. Gnant, M. Jakesz, R. Kaufmann, M. Boccardo, F. Godwin, J. Davies, C. Peto, R. (2010). Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J clin oncol, Vol.28 (3), pp. 509-518.  show abstract

Dowsett, M. (2010). Predictive and prognostic factors. Breast cancer res, Vol.12 Suppl 4, p. S2.

Sestak, I. Distler, W. Forbes, J.F. Dowsett, M. Howell, A. Cuzick, J. (2010). Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. Journal of clinical oncology, Vol.28 (21), pp. 3411-5.

Lonning, P.E. Dowsett, M. (2010). Endocrine Effects of Aromatase Inhibitors. Journal of clinical oncology, Vol.28 (6), pp. E101-2.

Jones, R.L. Rojo, F.G. A'Hern, R. Villena, N. Corominas, J. Servitja, S. Rovira, A. Reis-Filho, J.S. Dowsett, M. Albaneli, J. (2010). Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer. Journal of clinical oncology, Vol.28 (15).

Arnedos, M. Drury, S. Afentakis, M. Hills, M. Salter, J. Smith, I.E. Dowsett, M. (2010). Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. Journal of clinical oncology, Vol.28 (15).

Tang, G. Cuzick, J. Wale, C. Costantino, J.P. Crager, M. Shak, S. Wolmark, N. Dowsett, M. Forbes, J.F. (2010). Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach. Journal of clinical oncology, Vol.28 (15).

Banerjee, S. Zvelebil, M. Furet, P. Mueller-Vieira, U. Evans, D.B. Dowsett, M. Martin, L.-. (2009). The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. Cancer res, Vol.69 (11), pp. 4716-4723.  show abstract

Dowsett, M. (2009). The potential of new technologies/approaches Introduction to Sessions 3 and 4. Breast cancer research, Vol.11, p. 2.

McCormack, V.A. Dowsett, M. Folkerd, E. Johnson, N. Palles, C. Coupland, B. Holly, J.M. Vinnicombe, S.J. Perry, N.M. Silva, I.D. (2009). Sex steroids, growth factors and mammographic density: a cross-sectional study of UK postmenopausal Caucasian and Afro-Caribbean women. Breast cancer research, Vol.11 (3), p. 10.

Leary, A.F. Hanna, W.M. van de Vijver, M.J. Penault-Llorca, F. Rüschoff, J. Osamura, R.Y. Bilous, M. Dowsett, M. (2009). Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J clin oncol, Vol.27 (10), pp. 1694-1705.  show abstract

Penault-Llorca, F. Bilous, M. Dowsett, M. Hanna, W. Osamura, R.Y. Rueschoff, J. van de Vijver, M. (2009). Emerging Technologies for Assessing HER2 Amplification. American journal of clinical pathology, Vol.132 (4), pp. 539-10.

Roddam, A.W. Appleby, P. Neale, R. Dowsett, M. Folkerd, E. Tipper, S. Allen, N.E. Key, T.J. (2009). Association between endogenous plasma hormone concentrations and fracture risk in men and women: the EPIC-Oxford prospective cohort study. Journal of bone and mineral metabolism, Vol.27 (4), pp. 485-9.

Drury, S. Anderson, H. Dowsett, M. (2009). Selection of Reference Genes for Normalization of qRT-PCR Data Derived From FFPE Breast Tumors. Diagnostic molecular pathology, Vol.18 (2), pp. 103-5.

Murray, J. Young, O.E. Renshaw, L. White, S. Williams, L. Evans, D.B. Thomas, J.S. Dowsett, M. Dixon, J.M. (2009). A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Breast cancer research and treatment, Vol.114 (3), pp. 495-7.

Stone, J. Folkerd, E. Doody, D. Schroen, C. Treloar, S.A. Giles, G.G. Pike, M.C. English, D.R. Southey, M.C. Hopper, J.L. Dowsett, M. (2009). Familial Correlations in Postmenopausal Serum Concentrations of Sex Steroid Hormones and Other Mitogens: A Twins and Sisters Study. Journal of clinical endocrinology & metabolism, Vol.94 (12), pp. 4793-8.

Hilmi, C. Pancholi, S. Chaussade, C. Lykkesfeldt, A. Dowsett, M. Martin, L.-. (2009). PI3K associates with the ER/NCoR1 complex leading to suppression of ER genomic activity in tamoxifen resistant cells. Cancer research, Vol.69.

Sikora, M. Thibert, J. Salter, J. Dowsett, M. Johnson, M. Rae, J. (2009). High throughput SNP analysis from formalin-fixed, paraffin-embedded tumor tissues. Cancer research, Vol.69.

Sikora, M. Thibert, J. Salter, J. Dowsett, M. Johnson, M. Rae, J. (2009). High throughput SNP analysis from formalin-fixed, paraffin-embedded tumor tissues. Cancer research, Vol.69.

Jones, R.L. Salter, J. A'Hern, R. Nerurkar, A. Parton, M. Reis-Filho, J.S. Smith, I.E. Dowsett, M. (2009). The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast cancer res treat, Vol.116 (1), pp. 53-68.  show abstract

Attard, G. Reid, A.H. A'Hern, R. Parker, C. Oommen, N.B. Folkerd, E. Messiou, C. Molife, L.R. Maier, G. Thompson, E. Olmos, D. Sinha, R. Lee, G. Dowsett, M. Kaye, S.B. Dearnaley, D. Kheoh, T. Molina, A. de Bono, J.S. (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J clin oncol, Vol.27 (23), pp. 3742-3748.  show abstract

Arnedos, M. Nerurkar, A. Osin, P. A'Hern, R. Smith, I.E. Dowsett, M. (2009). Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann oncol, Vol.20 (12), pp. 1948-1952.  show abstract

Walker, K. Fletcher, O. Johnson, N. Coupland, B. McCormack, V.A. Folkerd, E. Gibson, L. Hillier, S.G. Holly, J.M. Moss, S. Dowsett, M. Peto, J. dos Santos Silva, I. (2009). Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer res, Vol.69 (16), pp. 6490-6499.  show abstract

Ellis, P. Barrett-Lee, P. Johnson, L. Cameron, D. Wardley, A. O'Reilly, S. Verrill, M. Smith, I. Yarnold, J. Coleman, R. Earl, H. Canney, P. Twelves, C. Poole, C. Bloomfield, D. Hopwood, P. Johnston, S. Dowsett, M. Bartlett, J.M. Ellis, I. Peckitt, C. Hall, E. Bliss, J.M. TACT Trial Management Group, TACT Trialists, (2009). Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet, Vol.373 (9676), pp. 1681-1692.  show abstract

Dowsett, M. Procter, M. McCaskill-Stevens, W. de Azambuja, E. Dafni, U. Rueschoff, J. Jordan, B. Dolci, S. Abramovitz, M. Stoss, O. Viale, G. Gelber, R.D. Piccart-Gebhart, M. Leyland-Jones, B. (2009). Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J clin oncol, Vol.27 (18), pp. 2962-2969.  show abstract

Dowsett, M. A'Hern, R. Salter, J. Zabaglo, L. Smith, I.E. (2009). Who would have thought a single Ki67 measurement would predict long-term outcome?. Breast cancer res, Vol.11 Suppl 3, p. S15.

Dixon, J.M. Renshaw, L. Young, O. Murray, J. Macaskill, E.J. McHugh, M. Folkerd, E. Cameron, D.A. A'Hern, R.P. Dowsett, M. (2008). Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J clin oncol, Vol.26 (10), pp. 1671-1676.  show abstract

Banerjee, S. Pancholi, S. A'hern, R. Ghazoui, Z. Smith, I.E. Dowsett, M. Martin, L.-. (2008). The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. Clin cancer res, Vol.14 (9), pp. 2656-2663.  show abstract

Attard, G. Reid, A.H. Yap, T.A. Raynaud, F. Dowsett, M. Settatree, S. Barrett, M. Parker, C. Martins, V. Folkerd, E. Clark, J. Cooper, C.S. Kaye, S.B. Dearnaley, D. Lee, G. de Bono, J.S. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J clin oncol, Vol.26 (28), pp. 4563-4571.  show abstract

Ellis, M.J. Tao, Y. Luo, J. A'Hern, R. Evans, D.B. Bhatnagar, A.S. Chaudri Ross, H.A. von Kameke, A. Miller, W.R. Smith, I. Eiermann, W. Dowsett, M. (2008). Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J natl cancer inst, Vol.100 (19), pp. 1380-1388.  show abstract

Urruticoechea, A. Arnedos, M. Walsh, G. Dowsett, M. Smith, I.E. (2008). Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC). Breast cancer research and treatment, Vol.110 (3), pp. 411-6.

Kendall, A. Anderson, H. Dunbier, A.K. Mackay, A. Dexter, T. Urruticoechea, A. Harper-Wynne, C. Dowsett, M. (2008). Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo. Cancer epidemiology biomarkers & prevention, Vol.17 (4), pp. 855-9.

Sanders, M.E. Dias, E.C. Xu, B.J. Mobley, J.A. Billheimer, D. Roder, H. Grigorieva, J. Dowsett, M. Arteaga, C.L. Caprioli, R.M. (2008). Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS. Journal of proteome research, Vol.7 (4), pp. 1500-8.

Dowsett, M. Allred, C. Knox, J. Quinn, E. Salter, J. Wale, C. Cuzick, J. Houghton, J. Williams, N. Mallon, E. Bishop, H. Ellis, I. Larsimont, D. Sasano, H. Carder, P. Cussac, A.L. Knox, F. Speirs, V. Forbes, J. Buzdar, A. (2008). Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J clin oncol, Vol.26 (7), pp. 1059-1065.  show abstract

Dowsett, M. (2008). Introduction to sessions on 'Predicting personal risk for breast cancer'. Breast cancer research, Vol.10, p. 2.

Thompson, D.J. Healey, C.S. Baynes, C. Kalmyrzaev, B. Ahmed, S. Dowsett, M. Folkerd, E. Luben, R.N. Cox, D. Ballinger, D. Pharoah, P.D. Ponder, B.A. Dunning, A.M. Easton, D.F. (2008). Identification of Common Variants on the SHBG Gene Affecting Sex Hormone-Binding Globulin Levels and Breast Cancer Risk in Postmenopausal Women. Cancer epidemiology biomarkers & prevention, Vol.17 (12), pp. 3490-9.

Walker, R.A. Bartlett, J.M. Dowsett, M. Ellis, I.O. Hanby, A.M. Jasani, B. Miller, K. Pinder, S.E. (2008). HER2 testing in the UK: further update to recommendations. Journal of clinical pathology, Vol.61 (7), pp. 818-7.

Fiegl, H. Jones, A. Hauser-Kronberger, C. Hutarew, G. Reitsamer, R. Jones, R.L. Dowsett, M. Mueller-Holzner, E. Windbichler, G. Daxenbichler, G. Goebel, G. Ensinger, C. Jacobs, I. Widschwendter, M. (2008). Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clinical cancer research, Vol.14 (11), pp. 3494-9.

Chan, M.-. Dowsett, M. Folkerd, E. Wareham, N. Luben, R. Welch, A. Bingham, S. Khaw, K.-. (2008). Past oral contraceptive and hormone therapy use and endogenous hormone concentrations in postmenopausal women. Menopause-the journal of the north american menopause society, Vol.15 (2), pp. 332-8.

Arriola, E. Marchio, C. Tan, D.S. Drury, S.C. Lambros, M.B. Natrajan, R. Rodriguez-Pinilla, S.M. Mackay, A. Tamber, N. Fenwick, K. Jones, C. Dowsett, M. Ashworth, A. Reis-Filho, J.S. (2008). Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab invest, Vol.88 (5), pp. 491-503.  show abstract

Urruticoechea, A. Aguilar, H. Solé, X. Capellà, G. Martin, L.-. Dowsett, M. Germà-Lluch, J.R. (2008). Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer. Breast cancer res treat, Vol.109 (3), pp. 463-470.  show abstract

Reis-Filho, J.S. Drury, S. Lambros, M.B. Marchio, C. Johnson, N. Natrajan, R. Salter, J. Levey, P. Fletcher, O. Peto, J. Ashworth, A. Dowsett, M. (2008). ESR1 gene amplification in breast cancer: a common phenomenon?. Nat genet, Vol.40 (7), pp. 809-810.

Thorpe, H. Brown, S.R. Sainsbury, J.R. Perren, T.J. Hiley, V. Dowsett, M. Nejim, A. Brown, J.M. (2008). Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: The ITS Study. British journal of cancer, Vol.98 (1), pp. 39-6.

Tan, D.S. Marchió, C. Jones, R.L. Savage, K. Smith, I.E. Dowsett, M. Reis-Filho, J.S. (2008). Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast cancer res treat, Vol.111 (1), pp. 27-44.  show abstract

Wolff, A.C. Berry, D. Carey, L.A. Colleoni, M. Dowsett, M. Ellis, M. Garber, J.E. Mankoff, D. Paik, S. Pusztai, L. Smith, M.L. Zujewski, J. (2008). Research issues affecting preoperative systemic therapy for operable breast cancer. Journal of clinical oncology, Vol.26 (5), pp. 806-8.

Pancholi, S. Lykkesfeldt, A.E. Hilmi, C. Banerjee, S. Leary, A. Drury, S. Johnston, S. Dowsett, M. Martin, L.-. (2008). ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr relat cancer, Vol.15 (4), pp. 985-1002.  show abstract

Dowsett, M. Dunbier, A.K. (2008). Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. Clinical cancer research, Vol.14 (24), pp. 8019-8.

De Bono, J.S. Attard, G. Reid, A.H. Parker, C. Dowsett, M. Mollife, R. Yap, T.A. Molina, A. Lee, G. Dearnaley, D. (2008). Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC). Journal of clinical oncology, Vol.26 (15).

Dowsett, M. (2008). Optimizing the implementation of future treatment using surrogate end-points. Breast cancer res, Vol.10 Suppl 4, p. S26.

Arriola, E. Lambros, M.B. Jones, C. Dexter, T. Mackay, A. Tan, D.S. Tamber, N. Fenwick, K. Ashworth, A. Dowsett, M. Reis-Filho, J.S. (2007). Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. Lab invest, Vol.87 (1), pp. 75-83.  show abstract

Bartlett, J.M. Ellis, I.O. Dowsett, M. Mallon, E.A. Cameron, D.A. Johnston, S. Hall, E. A'Hern, R. Peckitt, C. Bliss, J.M. Johnson, L. Barrett-Lee, P. Ellis, P. (2007). Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J clin oncol, Vol.25 (28), pp. 4423-4430.  show abstract

Dowsett, M. Salter, J. Hills, M. Detre, S. A'Hern, R. Smith, I.E. (2007). Short-term presurgical treatment for all?. Breast cancer research, Vol.9, p. 3.

Attard, G. Reid, A.H. Sinha, R. Molife, R. Raynaud, F. Dowsett, M. Barrett, M. Thompson, E. Yap, T.A. Settatree, S. Martins, V. Parker, C. Dearnaley, D. Folkerd, E. Lee, G. De Bono, J.S. (2007). Selective inhibition of CYP17 with abiraterone acetate is well tolerated and results in a high response rate in castration-resistant prostate cancer (CRPC). Molecular cancer therapeutics, Vol.6 (12), pp. 3455S-1.

Smith, I.E. Walsh, G. Skene, A. Llombart, A. Mayordomo, J.I. Detre, S. Salter, J. Clark, E. Magill, P. Dowsett, M. (2007). A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J clin oncol, Vol.25 (25), pp. 3816-3822.  show abstract

Santen, R.J. Boyd, N.F. Chlebowski, R.T. Cummings, S. Cuzick, J. Dowsett, M. Easton, D. Forbes, J.F. Key, T. Hankinson, S.E. Howell, A. Ingle, J. (2007). Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocrine-related cancer, Vol.14 (2), pp. 169-19.

Tworoger, S.S. Missmer, S.A. Eliassen, A.H. Barbieri, R.L. Dowsett, M. Hankinson, S.E. (2007). Physical activity and inactivity in relation to sex hormone, prolactin, and insulin-like growth factor concentrations in premenopausal women - Exercise and premenopausal hormones. Cancer causes & control, Vol.18 (7), pp. 743-10.

Chan, M.-. Dowsett, M. Folkerd, E. Bingham, S. Wareham, N. Luben, R. Welch, A. Khaw, K.-. (2007). Usual physical activity and endogenous sex hormones in postmenopausal women: The European prospective investigation into cancer - Norfolk Population Study. Cancer epidemiology biomarkers & prevention, Vol.16 (5), pp. 900-6.

Kaptoge, S. Dalzell, N. Folkerd, E. Doody, D. Khaw, K.-. Beck, T.J. Loveridge, N. Mawer, E.B. Berry, J.L. Shearer, M.J. Dowsett, M. Reeve, J. (2007). Sex hormone status may modulate rate of expansion of proximal femur diameter in older women alongside other skeletal regulators. Journal of clinical endocrinology & metabolism, Vol.92 (1), pp. 304-10.

Dowsett, M. Miller, W.R. (2007). Introduction to sessions on Personalising treatment. Breast cancer research, Vol.9, p. 2.

Dowsett, M. (2007). Chairperson's introduction. Ejc supplements, Vol.5 (5), pp. 75-1.

Low, Y.-. Dunning, A.M. Dowsett, M. Folkerd, E. Doody, D. Taylor, J. Bhaniani, A. Luben, R. Khaw, K.-. Wareham, N.J. Bingham, S.A. (2007). Phytoestrogen Exposure Is Associated with Circulating Sex Hormone Levels in Postmenopausal Women and Interact with ESR1 and NR1I2 Gene Variants. Cancer epidemiology biomarkers & prevention, Vol.16 (5), pp. 1009-1016.

Kendall, A. Folkerd, E.J. Dowsett, M. (2007). Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. J steroid biochem mol biol, Vol.103 (2), pp. 99-109.  show abstract

Arriola, E. Hui, E. Dowsett, M. Smith, I.E. (2007). Aromatase inhibitors and male breast cancer. Clin transl oncol, Vol.9 (3), pp. 192-194.  show abstract

Dowsett, M. Smith, I.E. (2007). Re: Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer - Response. Jnci-journal of the national cancer institute, Vol.99 (13), pp. 1053-2.

Khaw, K.-. Dowsett, M. Folkerd, E. Bingham, S. Wareham, N. Luben, R. Welch, A. Day, N. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation, Vol.116 (23), pp. 2694-8.

Dowsett, M. Hanna, W.M. Kockx, M. Penault-Llorca, F. Rüschoff, J. Gutjahr, T. Habben, K. van de Vijver, M.J. (2007). Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod pathol, Vol.20 (5), pp. 584-591.  show abstract

Smith, I. Procter, M. Gelber, R.D. Guillaume, S. Feyereislova, A. Dowsett, M. Goldhirsch, A. Untch, M. Mariani, G. Baselga, J. Kaufmann, M. Cameron, D. Bell, R. Bergh, J. Coleman, R. Wardley, A. Harbeck, N. Lopez, R.I. Mallmann, P. Gelmon, K. Wilcken, N. Wist, E. Sánchez Rovira, P. Piccart-Gebhart, M.J. HERA study team, (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet, Vol.369 (9555), pp. 29-36.  show abstract

Jones, M.E. Folkerd, E.J. Doody, D.A. Iqbal, J. Dowsett, M. Ashworth, A. Swerdlow, A.J. (2007). Effect of delays in processing blood samples on measured endogenous plasma sex hormone levels in women. Cancer epidemiol biomarkers prev, Vol.16 (6), pp. 1136-1139.  show abstract

Dowsett, M. Hanby, A.M. Laing, R. Walker, R. National HER2 Consultation Steering Group, (2007). HER2 testing in the UK: consensus from a national consultation. J clin pathol, Vol.60 (6), pp. 685-689.  show abstract

Powles, T.J. Ashley, S. Smith, I.E. Dowsett, M. (2007). "Untitled". Jnci-journal of the national cancer institute, Vol.99 (21), pp. 1645-2.

Johnston, S.R. Martin, L.-. Leary, A. Head, J. Dowsett, M. (2007). Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J steroid biochem mol biol, Vol.106 (1-5), pp. 180-186.  show abstract

Anderson, H. Bulun, S. Smith, I. Dowsett, M. (2007). Predictors of response to aromatase inhibitors. J steroid biochem mol biol, Vol.106 (1-5), pp. 49-54.  show abstract

Martin, L.-. Head, J.E. Pancholi, S. Salter, J. Quinn, E. Detre, S. Kaye, S. Howes, A. Dowsett, M. Johnston, S.R. (2007). The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. Mol cancer ther, Vol.6 (9), pp. 2458-2467.  show abstract

Banerjee, S. Dowsett, M. Ashworth, A. Martin, L.-. (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat clin pract oncol, Vol.4 (9), pp. 536-550.  show abstract

Arriola, E. Rodriguez-Pinilla, S.M. Lambros, M.B. Jones, R.L. James, M. Savage, K. Smith, I.E. Dowsett, M. Reis-Filho, J.S. (2007). Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast cancer res treat, Vol.106 (2), pp. 181-189.  show abstract

Kubista, E. Gomez, J.V. Dowsett, M. Foidart, J.-. Pohlodek, K. Serreyn, R. Nechushkin, M. Manikhas, A.G. Semiglazov, V.F. Hageluken, C.C. Singer, C.F. (2007). Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: Results from STEM trial. Clinical cancer research, Vol.13 (14), pp. 4185-6.

Dowsett, M. Smith, I.E. Ebbs, S.R. Dixon, J.M. Skene, A. A'Hern, R. Salter, J. Detre, S. Hills, M. Walsh, G. IMPACT Trialists Group, (2007). Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J natl cancer inst, Vol.99 (2), pp. 167-170.  show abstract

Kote-Jarai, Z. Powles, T.J. Mitchell, G. Tidy, A. Ashley, S. Easton, D. Assersohn, L. Sodha, N. Salter, J. Gusterson, B. Dowsett, M. Eeles, R. (2007). BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer lett, Vol.247 (2), pp. 259-265.  show abstract

Powles, T.J. Ashley, S. Tidy, A. Dowsett, M. (2007). Twenty-year follow-up of the royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. Jnci-journal of the national cancer institute, Vol.99 (4), pp. 283-8.

Pierga, J.-. Reis-Filho, J.S. Cleator, S.J. Dexter, T. Mackay, A. Simpson, P. Fenwick, K. Iravani, M. Salter, J. Hills, M. Jones, C. Ashworth, A. Smith, I.E. Powles, T. Dowsett, M. (2007). Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br j cancer, Vol.96 (2), pp. 341-351.  show abstract

Mackay, A. Urruticoechea, A. Dixon, J.M. Dexter, T. Fenwick, K. Ashworth, A. Drury, S. Larionov, A. Young, O. White, S. Miller, W.R. Evans, D.B. Dowsett, M. (2007). Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast cancer res, Vol.9 (3), p. R37.  show abstract

Dowsett, M. Goldhirsch, A. Hayes, D.F. Senn, H.-. Wood, W. Viale, G. (2007). International Web-based consultation on priorities for translational breast cancer research. Breast cancer res, Vol.9 (6), p. R81.  show abstract

Dowsett, M. Smith, I.E. Ebbs, S.R. Dixon, J.M. Skene, A. Griffith, C. Boeddinghaus, I. Salter, J. Detre, S. Hills, M. Ashley, S. Francis, S. Walsh, G. A'Hern, R. (2006). Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin cancer res, Vol.12 (3 Pt 2), pp. 1024s-1030s.  show abstract

Smith, I.E. Dowsett, M. Yap, Y.-. Walsh, G. Lønning, P.E. Santen, R.J. Hayes, D. (2006). Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J clin oncol, Vol.24 (16), pp. 2444-2447.  show abstract

Tworoger, S.S. Eliassen, A.H. Missmer, S.A. Baer, H. Rich-Edwards, J. Michels, K.B. Barbieri, R.L. Barbieri, R.L. Dowsett, M. Hankinson, S.E. (2006). Birthweight and body size throughout life in relation to sex hormones and prolactin concentrations in premenopausal women. Cancer epidemiology biomarkers & prevention, Vol.15 (12), pp. 2494-8.

Lee, J.S. Ettinger, B. Stanczyk, F.Z. Vittinghoff, E. Hanes, V. Cauley, J.A. Chandler, W. Settlage, J. Beattie, M.S. Folkerd, E. Dowsett, M. Grady, D. Cummings, S.R. (2006). Comparison of methods to measure low serum estradiol levels in postmenopausal women. Journal of clinical endocrinology & metabolism, Vol.91 (10), pp. 3791-7.

Warren, R. Skinner, J. Sala, E. Denton, E. Dowsett, M. Folkerd, E. Healey, C.S. Dunning, A. Doody, D. Ponder, B. Luben, R.N. Day, N.E. Easton, D. (2006). Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer epidemiology biomarkers & prevention, Vol.15 (8), pp. 1502-7.

Eastell, R. Hannon, R.A. Cuzick, J. Dowsett, M. Clack, G. Adams, J.E. (2006). Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). Journal of bone and mineral research, Vol.21 (8), pp. 1215-9.

Burcombe, R. D Wilson, G. Dowsett, M. Khan, I. Richman, P.I. Daley, F. Detre, S. Makris, A. (2006). Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast cancer research, Vol.8 (3), p. 10.

Tworoger, S.S. Missmer, S.A. Eliassen, A.H. Spiegelman, D. Folkerd, E. Dowsett, M. Barbieri, R.L. Hankinson, S.E. (2006). The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer epidemiology biomarkers & prevention, Vol.15 (5), pp. 967-5.

Schernhammer, E.S. Kroenke, C.H. Dowsett, M. Folkerd, E. Hankinson, S.E. (2006). Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levels. Journal of pineal research, Vol.40 (2), pp. 116-9.

Cleator, S. Tsimelzon, A. Ashworth, A. Dowsett, M. Dexter, T. Powles, T. Hilsenbeck, S. Wong, H. Osborne, C.K. O'Connell, P. Chang, J.C. (2006). Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast cancer res treat, Vol.95 (3), pp. 229-233.  show abstract

Kendall, A. Dowsett, M. Folkerd, E. Smith, I. (2006). Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann oncol, Vol.17 (4), pp. 584-587.  show abstract

Eliassen, A.H. Missmer, S.A. Tworoger, S.S. Spiegelman, D. Barbieri, R.L. Dowsett, M. Hankinson, S.E. (2006). Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Jnci-journal of the national cancer institute, Vol.98 (19), pp. 1406-10.

Dowsett, M. Houghton, J. Iden, C. Salter, J. Farndon, J. A'Hern, R. Sainsbury, R. Baum, M. (2006). Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann oncol, Vol.17 (5), pp. 818-826.  show abstract

Reis-Filho, J.S. Savage, K. Lambros, M.B. James, M. Steele, D. Jones, R.L. Dowsett, M. (2006). Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod pathol, Vol.19 (7), pp. 999-1009.  show abstract

Kendall, A. Dowsett, M. (2006). Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr relat cancer, Vol.13 (3), pp. 827-837.  show abstract

Dowsett, M. Urruticoechea, A. Smith, I.E. (2006). Ki-67 correlates with in vivo bromodeoxyuridine labeling index in operable breast cancer - Reply. Journal of clinical oncology, Vol.24 (23), pp. 3809-1.

Amin, A.A. Huang, C.-. Reierstad, S. Lin, Z. Arbieva, Z. Wiley, E. Saborian, H. Haynes, B. Cotterill, H. Dowsett, M. Bulun, S.E. (2006). Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. Molecular and cellular endocrinology, Vol.253 (1-2), pp. 44-12.

Folkerd, E.J. Martin, L.-. Kendall, A. Dowsett, M. (2006). The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer. J steroid biochem mol biol, Vol.102 (1-5), pp. 250-255.  show abstract

Low, Y.-. Dunning, A.M. Dowsett, M. Luben, R.N. Khaw, K.-. Wareham, N.J. Bingham, S.A. (2006). Implications of gene-environment interaction in studies of gene variants in breast cancer: An example of dietary isoflavones and the D356N polymorphism in the sex hormone-binding globulin gene. Cancer research, Vol.66 (18), pp. 8980-4.

Leary, A. Dowsett, M. (2006). Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?. Br j cancer, Vol.95 (6), pp. 661-666.  show abstract

Beattie, M.S. Costantino, J.P. Cummings, S.R. Wickerham, D.L. Vogel, V.G. Dowsett, M. Folkerd, E.J. Willett, W.C. Wolmark, N. Hankinson, S.E. (2006). Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). Jnci-journal of the national cancer institute, Vol.98 (2), pp. 110-6.

Beattie, M.S. Costantino, J.P. Cummings, S.R. Wickerham, D.L. Vogel, V.G. Dowsett, M. Folkerd, E.J. Willett, W.C. Wolmark, N. Hankinson, S.E. (2006). Endogenous Sex Hormones, Breast Cancer Risk, and Tamoxifen Response: An Ancillary Study in the NSABP Breast Cancer Prevention Trial (P-1). Jnci: journal of the national cancer institute, Vol.98 (2), pp. 110-115.

Dowsett, M. (2006). Estrogen receptor: Methodology matters. Journal of clinical oncology, Vol.24 (36), pp. 5626-3.

Dowsett, M. Cuzick, J. Wale, C. Howell, T. Houghton, J. Baum, M. Buzdar, A. (2006). Progesterone receptor and human epidermal growth factor receptor 2 status: An independent influence on the efficacy of endocrine therapy in breast cancer? Reply. Journal of clinical oncology, Vol.24 (9), pp. 1482-1.

Dixon, J.M. Renshaw, L. Young, O. Murray, J. Macaskill, E.J. McHugh, M. Folkerd, E. Cameron, D. Dowsett, M. (2006). Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. J clin oncol, Vol.24 (18_suppl), p. 552.  show abstract

Kendall, A. Smith, I. Folkerd, E. Dowsett, M. (2006). Aromatase inhibition and very low dose estradiol add-back: A pilot study for novel breast cancer prevention. J clin oncol, Vol.24 (18_suppl), p. 1014.  show abstract

Dowsett, M. Smith, I. Skene, A. Llombart, A. Mayordomo, J. Detre, S. Salter, J. Beresford, E. Magill, P. Study 0223 Trialists, (2006). Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). J clin oncol, Vol.24 (18_suppl), p. 515.  show abstract

Cleator, S.J. Powles, T.J. Dexter, T. Fulford, L. Mackay, A. Smith, I.E. Valgeirsson, H. Ashworth, A. Dowsett, M. (2006). The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast cancer res, Vol.8 (3), p. R32.  show abstract

Low, Y.L. Taylor, J.I. Grace, P.B. Dowsett, M. Folkerd, E. Doody, D. Dunning, A.M. Scollen, S. Mulligan, A.A. Welch, A.A. Luben, R.N. Khaw, K.T. Day, N.E. Wareham, N.J. Bingham, S.A. (2005). Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men. Journal of nutrition, Vol.135 (11), pp. 2680-7.

Low, Y.L. Taylor, J.I. Grace, P.B. Dowsett, M. Scollen, S. Dunning, A.M. Mulligan, A.A. Welch, A.A. Luben, R.N. Khaw, K.T. Day, N.E. Wareham, N.J. Bingham, S.A. (2005). Phytoestrogen exposure correlation with plasma estradiol in postmenopausal women in European Prospective Investigation of Cancer and Nutrition-Norfolk may involve diet-gene interactions. Cancer epidemiology biomarkers & prevention, Vol.14 (1), pp. 213-8.

Smith, I.E. Dowsett, M. Ebbs, S.R. Dixon, J.M. Skene, A. Blohmer, J.-. Ashley, S.E. Francis, S. Boeddinghaus, I. Walsh, G. IMPACT Trialists Group, (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J clin oncol, Vol.23 (22), pp. 5108-5116.  show abstract

Urruticoechea, A. Smith, I.E. Dowsett, M. (2005). Proliferation marker Ki-67 in early breast cancer. J clin oncol, Vol.23 (28), pp. 7212-7220.  show abstract

Martin, L.A. Pancholi, S. Chan, C.M. Farmer, I. Kimberley, C. Dowsett, M. Johnston, S.R. (2005). The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocrine-related cancer, Vol.12 (4), pp. 1017-20.

Chen, B. Gajdos, C. Dardes, R. Kidwai, N. Johnston, S.R. Dowsett, M. Jordan, V.C. (2005). Potential of endogenous estrogen receptor beta to influence the selective ER modulator ER beta complex. International journal of oncology, Vol.27 (2), pp. 327-9.

Howell, A. Cuzick, J. Baum, M. Buzdar, A. Dowsett, M. Forbes, J.F. Hoctin-Boes, G. Houghton, I. Locker, G.Y. Tobias, J.S. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, Vol.365 (9453), pp. 60-3.

Dowsett, M. Hanna, W. Kockx, M. Penault-Llorca, F. Rueschoff, J. Gutjahr, T. Habben, K. van de Vijver, M. (2005). Standardisation of HER2 testing: results of an international proficiency testing ring study. Ejc supplements, Vol.3 (2), pp. 72-1.

Esserman, L.J. Ozanne, E.M. Dowsett, M. Slingerland, J.M. (2005). Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. Breast cancer research, Vol.7 (6), pp. R1153-6.

Johnston, S.R. Martin, L.-. Head, J. Smith, I. Dowsett, M. (2005). Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J steroid biochem mol biol, Vol.95 (1-5), pp. 173-181.  show abstract

Dowsett, M. Martin, L.-. Smith, I. Johnston, S. (2005). Mechanisms of resistance to aromatase inhibitors. J steroid biochem mol biol, Vol.95 (1-5), pp. 167-172.  show abstract

Martin, L.-. Farmer, I. Johnston, S.R. Ali, S. Dowsett, M. (2005). Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr relat cancer, Vol.12 Suppl 1, pp. S75-S84.  show abstract

Dowsett, M. Johnston, S. Martin, L.-. Salter, J. Hills, M. Detre, S. Gutierrez, M.C. Mohsin, S.K. Shou, J. Allred, D.C. Schiff, R. Osborne, C.K. Smith, I. (2005). Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr relat cancer, Vol.12 Suppl 1, pp. S113-S117.  show abstract

Dowsett, M. Ebbs, S.R. Dixon, J.M. Skene, A. Griffith, C. Boeddinghaus, I. Salter, J. Detre, S. Hills, M. Ashley, S. Francis, S. Walsh, G. Smith, I.E. (2005). Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J clin oncol, Vol.23 (11), pp. 2477-2492.  show abstract

Banerjee, S. Smith, I.E. Folkerd, L. Iqbal, J. Barker, P. Dowsett, M. IMPACT trialists, (2005). Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann oncol, Vol.16 (10), pp. 1632-1638.  show abstract

Gutierrez, M.C. Detre, S. Johnston, S. Mohsin, S.K. Shou, J.N. Allred, D.C. Schiff, R. Osborne, C.K. Dowsett, M. (2005). Molecular changes in tamoxifen-resistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. Journal of clinical oncology, Vol.23 (11), pp. 2469-8.

Dowsett, M. Folkerd, E. Doody, D. Haynes, B. (2005). The biology of steroid hormones and endocrine treatment of breast cancer. Breast, Vol.14 (6), pp. 452-457.  show abstract

Ring, A.E. Zabaglo, L. Ormerod, M.G. Smith, I.E. Dowsett, M. (2005). Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br j cancer, Vol.92 (5), pp. 906-912.  show abstract

Dowsett, M. Smith, I.E. Ebbs, S.R. Dixon, J.M. Skene, A. Griffith, C. Boeddinghaus, I. Salter, J. Detre, S. Hills, M. Ashley, S. Francis, S. Walsh, G. IMPACT Trialists, (2005). Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin cancer res, Vol.11 (2 Pt 2), pp. 951s-958s.  show abstract

Dunning, A.M. Dowsett, M. Healey, C.S. Luben, R.N. Folkerd, E. Pharoah, P.D. Easton, D.F. Bruce, N.E. Ponder, A.J. (2005). Re: Polymorphisms associated with circulating sex hormone levels in postmenopausal women - Response. Jnci-journal of the national cancer institute, Vol.97 (2), pp. 153-2.

Piccart-Gebhart, M.J. Procter, M. Leyland-Jones, B. Goldhirsch, A. Untch, M. Smith, I. Gianni, L. Baselga, J. Bell, R. Jackisch, C. Cameron, D. Dowsett, M. Barrios, C.H. Steger, G. Huang, C.S. Andersson, M. Inbar, M. Lichinitser, M. Lang, I. Nitz, U. Iwata, H. Thomssen, C. Lohrisch, C. Suter, T.M. Ruschoff, J. Suto, T. Greatorex, V. Ward, C. Straehle, C. McFadden, E. Dolci, M.S. Gelber, R.D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New england journal of medicine, Vol.353 (16), pp. 1659-14.

Dowsett, M. Cuzick, J. Wale, C. Howell, T. Houghton, J. Baum, M. (2005). Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J clin oncol, Vol.23 (30), pp. 7512-7517.  show abstract

Johnston, S.R. Martin, L.-. Dowsett, M. (2005). Life following aromatase inhibitors--where now for endocrine sequencing?. Breast cancer res treat, Vol.93 Suppl 1, pp. S19-S25.  show abstract

Dowsett, M. Folkerd, E. (2005). Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast cancer res, Vol.7 (1), pp. 1-4.  show abstract

Dowsett, M. Nicholson, R.I. Pietras, R.J. (2005). Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast cancer res treat, Vol.93 Suppl 1, pp. S11-S18.  show abstract

Dowsett, M. (2004). Molecular basis of endocrine therapy. Ejc supplements, Vol.2 (3), pp. 12-2.

Grace, P.B. Taylor, J.I. Low, Y.L. Luben, R.N. Mulligan, A.A. Botting, N.P. Dowsett, M. Welch, A.A. Khaw, K.T. Wareham, N.J. Day, N.E. Bingham, S.A. (2004). Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective Investigation of Cancer and Nutrition-Norfolk. Cancer epidemiology biomarkers & prevention, Vol.13 (5), pp. 698-11.

Atkinson, C. Warren, R.M. Sala, E. Dowsett, M. Dunning, A.M. Healey, C.S. Runswick, S. Day, N.E. Bingham, S.A. (2004). Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165]. Breast cancer research, Vol.6 (3), pp. R170-10.

Ellis, I.O. Bartlett, J. Dowsett, M. Humphreys, S. Jasani, B. Miller, K. Pinder, S.E. Rhodes, A. Walker, R. (2004). Updated recommendations for HER2 testing in the UK. Journal of clinical pathology, Vol.57 (3), pp. 233-5.

Atkinson, C. Compston, J.E. Day, N.E. Dowsett, M. Bingham, S.A. (2004). The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. American journal of clinical nutrition, Vol.79 (2), pp. 326-8.

Dixon, J.M. Jackson, J. Hills, M. Renshaw, L. Cameron, D.A. Anderson, T.J. Miller, W.R. Dowsett, M. (2004). Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. European journal of cancer, Vol.40 (18), pp. 2742-6.

Howell, A. Dowsett, M. (2004). Endocrinology and hormone therapy in breast cancer - Aromatase inhibitors versus antioestrogens. Breast cancer research, Vol.6 (6), pp. 269-6.

Gumbrell, L.A. Evans, T.R. Coleman, R.E. Smith, I.E. Twelves, C.J. Soukop, M. Rea, D.W. Earl, H.M. Howell, A. Jones, A. Canney, P. Powles, T.J. Haynes, B.P. Nutley, B. Grimshaw, R. Jarman, M. Halbert, G.W. Brampton, M. Haviland, J. Dowsett, M. Coombes, R.C. Johnston, S.R. (2004). A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer chemotherapy and pharmacology, Vol.53 (4), pp. 341-348.

Ring, A. Smith, I.E. Dowsett, M. (2004). Circulating tumour cells in breast cancer. Lancet oncol, Vol.5 (2), pp. 79-88.  show abstract

Parton, M. Dowsett, M. Ashley, S. Hills, M. Lowe, F. Smith, I.E. (2004). High incidence of HER-2 positivity in inflammatory breast cancer. Breast, Vol.13 (2), pp. 97-103.  show abstract

Ring, A. Dowsett, M. (2004). Mechanisms of tamoxifen resistance. Endocr relat cancer, Vol.11 (4), pp. 643-658.  show abstract

O'Donnell, A. Judson, I. Dowsett, M. Raynaud, F. Dearnaley, D. Mason, M. Harland, S. Robbins, A. Halbert, G. Nutley, B. Jarman, M. (2004). Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br j cancer, Vol.90 (12), pp. 2317-2325.  show abstract

Cuzick, J. Buzdar, A. Baum, M. Bianco, R. Coleman, R. Constenla, M. Distler, W. Dowsett, M. Forbes, J. Guastalla, J.P. Houghton, J. Williams, N. Howell, A. Locker, G. MacKey, J. Sainsbury, R. Tobias, J. (2004). Adjuvant use of anastrozole in breast cancer. Journal of clinical oncology, Vol.22 (8), pp. 1524-3.

Dowsett, M. Smith, I.E. IMPACT Trialists, (2004). Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer. J clin oncol, Vol.22 (14_suppl), p. 537.  show abstract

Smith, I.E. Dowsett, M. IMPACT Trialists, (2004). Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial. J clin oncol, Vol.22 (14_suppl), p. 675.  show abstract

Dunning, A.M. Dowsett, M. Healey, C.S. Tee, L. Luben, R.N. Folkerd, E. Novik, K.L. Kelemen, L. Ogata, S. Pharoah, P.D. Easton, D.F. Day, N.E. Ponder, B.A. (2004). Polymorphisms associated with circulating sex hormone levels in postmenopausal women. Jnci-journal of the national cancer institute, Vol.96 (12), pp. 936-10.

Dowsett, M. (2004). Translational research and the changing face of breast cancer. Breast cancer res treat, Vol.87 Suppl 1, pp. S1-S2.  show abstract

Dowsett, M. (2004). Biomarker investigations from the ATAC trial: the role of TA01. Breast cancer res treat, Vol.87 Suppl 1, pp. S11-S18.  show abstract

Dowsett, M. (2004). Designing the future shape of breast cancer diagnosis, prognosis and treatment. Breast cancer res treat, Vol.87 Suppl 1, pp. S27-S29.  show abstract

Johnston, S.R. Hickish, T. Ellis, P. Houston, S. Kelland, L. Dowsett, M. Salter, J. Michiels, B. Perez-Ruixo, J.J. Palmer, P. Howes, A. (2003). Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. Journal of clinical oncology, Vol.21 (13), pp. 2492-8.

Johnston, S.R. Head, J. Pancholi, S. Detre, S. Martin, L.-. Smith, I.E. Dowsett, M. (2003). Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin cancer res, Vol.9 (1 Pt 2), pp. 524S-532S.  show abstract

Dowsett, M. (2003). Preoperative models to evaluate endocrine strategies for breast cancer. Clin cancer res, Vol.9 (1 Pt 2), pp. 502S-510S.  show abstract

Detre, S. Riddler, S. Salter, J. A'Hern, R. Dowsett, M. Johnston, S.R. (2003). Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. Cancer res, Vol.63 (19), pp. 6516-6522.  show abstract

Bilous, M. Dowsett, M. Hanna, W. Isola, J. Lebeau, A. Moreno, A. Penault-Llorca, F. Ruschoff, J. Tomasic, G. de Vijver, M.V. (2003). Current perspectives on HER2 testing: A review of national testing guidelines. Modern pathology, Vol.16 (2), pp. 173-10.

Come, S.E. Buzdar, A.U. Arteaga, C.L. Brodie, A.M. Davidson, N.E. Dowsett, M. Ingle, J.N. Johnston, S.R. Lee, A.V. Osborne, C.K. Pritchard, K.I. Vogel, V.G. Winer, E.P. Hart, C.S. (2003). Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Summary consensus statement. Clinical cancer research, Vol.9 (1), pp. 443S-4.

Dowsett, M. Bartlett, J. Ellis, I.O. Salter, J. Hills, M. Mallon, E. Watters, A.D. Cooke, T. Paish, C. Wencyk, P.M. Pinder, S.E. (2003). Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J pathol, Vol.199 (4), pp. 418-423.  show abstract

Ring, A. Dowsett, M. (2003). Human epidermal growth factor receptor-2 and hormonal therapies: clinical implications. Clin breast cancer, Vol.4 Suppl 1, pp. S34-S41.  show abstract

Davies, G. Salter, J. Hills, M. Martin, L.-. Sacks, N. Dowsett, M. (2003). Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin cancer res, Vol.9 (7), pp. 2651-2656.  show abstract

Dowsett, M. Ellis, M.J. (2003). Role of biologic markers in patient selection and application to disease prevention. Am j clin oncol, Vol.26 (4), pp. S34-S39.  show abstract

Dowsett, M. (2003). Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin oncol, Vol.30 (4 Suppl 14), pp. 58-69.  show abstract

Dowsett, M. Haynes, B.P. (2003). Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J steroid biochem mol biol, Vol.86 (3-5), pp. 255-263.  show abstract

Zabaglo, L. Ormerod, M.G. Parton, M. Ring, A. Smith, I.E. Dowsett, M. (2003). Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells. Cytometry a, Vol.55 (2), pp. 102-108.  show abstract

Haynes, B.P. Dowsett, M. Miller, W.R. Dixon, J.M. Bhatnagar, A.S. (2003). The pharmacology of letrozole. J steroid biochem mol biol, Vol.87 (1), pp. 35-45.  show abstract

Zabaglo, L. Ormerod, M.G. Dowsett, M. (2003). Measurement of proliferation marker Ki67 in breast tumour FNAs using laser scanning cytometry in comparison to conventional immunocytochemistry. Cytometry b clin cytom, Vol.56 (1), pp. 55-61.  show abstract

Johnston, S.R. Dowsett, M. (2003). Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat rev cancer, Vol.3 (11), pp. 821-831.

Assersohn, L. Salter, J. Powles, T.J. A'hern, R. Makris, A. Gregory, R.K. Chang, J. Dowsett, M. (2003). Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast cancer res treat, Vol.82 (2), pp. 113-123.  show abstract

Dowsett, M. (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, Vol.98, pp. 1802-1810.  show abstract

Smith, I.E. Dowsett, M.